resourceId,targetAntigen,hostOrganism,clonality,cloneId,uniprotId,reactiveSpecies,conjugate,_resourceName,_pmid,_doi,_publicationTitle,_year,_context,_confidence,_verdict,_usageType
,tyrosine hydroxylase,Rabbit,Polyclonal,,,,Non-conjugated,tyrosine hydroxylase,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000) | Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000),0.9,Accept,Experimental Usage
,GFP,Rabbit,Unknown,,,,,GFP,PMID:34415582 | PMID:41022755 | PMID:40590220 | PMID:31545171 | PMID:31015291 | PMID:32461556 | PMID:29715273 | PMID:36890585 | PMID:34257279,10.1002/glia.24075 | 10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.7554/eLife.48983 | 10.1126/scisignal.aau8749 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1186/s40478-023-01525-w | 10.1038/s41467-021-24505-x,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"Primary antibodies used in this study: Rabbit anti-GFP, Thermo Fisher, Cat. # A6455 (1/1000) | rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies | Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals | GFP (ab1218, Abcam, Western blotting and Invitrogen, IP) | Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000) | Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland | GFP Life Technologies, A11122 1:1000 Overnight, RT Citrate buffer, pH 6.0 | anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany) | chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK) | Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)",0.95,Accept,Experimental Usage
,TRIM23,Rabbit,Polyclonal,,,,,TRIM23,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,"Immunohistochemical stain for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal)",0.95,Accept,Experimental Usage
,H3K27me3,Rabbit,Monoclonal,,,,,H3K27me3,PMID:32642734 | PMID:31462295 | PMID:39321200 | PMID:30479396 | PMID:38127282 | PMID:38216572 | PMID:37246765 | PMID:36598417,10.1093/noajnl/vdz026 | 10.1186/s40478-019-0792-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/2159-8290.CD-22-0786,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Telomere alterations in neurofibromatosis type 1-associated solid tumors. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"Immunohistochemistry for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50 dilution; Cell Signaling Technology) | using a mouse monoclonal antibody (Abcam, Cat# ab6002, Cambridge, MA) at 1:1600 dilution | IHC for H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:100 dilution) was performed on FFPE whole slide tissue sections | H3K27Me3 (Cell Signaling, 9733 S, 1:500) | H3K27me3 (9733S, 1:100, Cell Signaling) | H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:50 dilution) | H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.95,Accept,Experimental Usage
,Cleaved-caspase 3,,,,,,,Cleaved-caspase 3,PMID:32642734 | PMID:32461556 | PMID:38502231 | PMID:24509877 | PMID:36322658 | PMID:34040258 | PMID:35511749 | PMID:26904939 | PMID:36241865 | PMID:24817309,10.1093/noajnl/vdz026 | 10.1038/s41467-020-16432-0 | 10.1172/JCI176748 | 10.1038/onc.2013.506 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1158/1535-7163.MCT-21-0947 | 10.1016/j.celrep.2016.01.074 | 10.1038/s12276-022-00850-9 | 10.1371/journal.pone.0097320,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,"Immunohistochemical staining for Cleaved-caspase 3 at 1:500 (Cell Signaling Technology, Danvers, MA) | Cleaved Caspase-3 (D175) Cell Signaling Technology, #9661L 1:500 Overnight, RT Citrate buffer, pH 6.0 | cleaved caspase 3 (9661S, Cell Signaling Technology) | Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako), MBP (Chemicon), BLBP (Millipore), DEPTOR (Novus), cleaved-caspase 3 | cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661), BrdU (rat; Abcam, ab6326) | rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A | Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology | anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA) | Anti-cleaved caspase-3 antibody primary IF and WB CST | cleaved caspase-3+ cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)",0.9,Accept,Experimental Usage
,Ki67,Rabbit,Monoclonal,,,,,Ki67,PMID:40394150 | PMID:32699356 | PMID:32948135 | PMID:32642734 | PMID:35589737 | PMID:19191334 | PMID:32461556 | PMID:29715273 | PMID:34040258 | PMID:35945463 | PMID:29941005 | PMID:29438698 | PMID:24681606 | PMID:30055648 | PMID:33032988 | PMID:26904939 | PMID:40684195 | PMID:32642733 | PMID:36148553 | PMID:33356508 | PMID:37246765 | PMID:24371224 | PMID:25535838 | PMID:33591953 | PMID:38945076 | PMID:34930951 | PMID:39996452 | PMID:21216928,10.1038/s41416-025-03055-9 | 10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1093/noajnl/vdz026 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1038/s41467-020-16432-0 | 10.1371/journal.pone.0196726 | 10.1038/s41586-021-03580-6 | 10.1007/s00401-022-02478-5 | 10.1186/s13023-018-0843-1 | 10.1016/j.ccell.2018.01.005 | 10.18632/oncotarget.1609 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-20-1365 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1093/noajnl/vdz061 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151 | 10.1172/jci.insight.146351 | 10.1016/j.redox.2024.103249 | 10.1038/s41536-021-00195-3 | 10.1111/cns.70287 | 10.1158/1535-7163.MCT-10-0654,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin. | Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)... | mouse anti-Ki67 (550609, 1:500, BD Pharmingen) | proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO) | prediluted Ki67 (790–4286; Ventana) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Ki-67 (BD Pharmingen, San Diego, CA) antibodies followed by Vectastain ABC development | KI67 Monosan, MONX10283 1:2000 Overnight, RT Citrate buffer, pH 6.0 | anti Ki67 (15580, 1:500, Abcam, Cambridge, UK) | using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549) | Ki-67 (Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval) | ...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)... | Ki67 (Rabbit; Thermo Fisher Scientific, RM-9106), BrdU (Rat; Abcam, ab6326) | primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200)) | anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9) to evaluate proliferation fraction | Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam) | Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL) | rabbit anti-Ki67 (1:200; Abcam #ab15580) | Ki67 (Ventana Medical Systems) | Ki67 (1:100; ab15580; Abcam) | Ki67-FITC (proliferation marker) | Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology) | Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako) | Ki-67 (1:500, mouse, BD Pharmingen) | staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam), KI-67 (prediluted; catalog 790-4286, Ventana) | Cells were stained with antibodies specific for Ki-67 (1:800 dilution, Cat. no. 9449, Cell Signaling) | examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam. | immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described",0.95,Accept,Experimental Usage
,GFAP,Mouse,Monoclonal,,,,,GFAP,PMID:32699356 | PMID:18451155 | PMID:35589737 | PMID:19191334 | PMID:35945463 | PMID:20554030 | PMID:33356508 | PMID:25535838 | PMID:34930951 | PMID:25772366 | PMID:36241865 | PMID:20551058 | PMID:19144871,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1038/s41467-022-30466-6 | 10.1002/glia.20845 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1177/0963689720964383 | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1016/j.celrep.2015.02.041 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769 | 10.3181/0809-RM-275,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen) | β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO) | Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA) | glial fibrillary acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval) | Invitrogen (Rat anti-GFAP) | labeled overnight at room temperature with the following conjugated primary antibodies: S100-FITC, Vimentin-FTIC, CD45-APC, Ki67-APC, and GFAP-APC | GFAP (1:2000, rabbit, DAKO, Carpinteria, CA) | Every 6th section was stained with GFAP-PE (Muller cells marker) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte) | Anti-GFAP antibody primary IF and WB CST | Invitrogen (GFAP) | mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA)",0.95,Accept,Experimental Usage
,Iba-1,Unknown,Monoclonal,,,Mouse,Non-conjugated,Iba-1,PMID:36890585 | PMID:35589737 | PMID:38502231 | PMID:36322658 | PMID:34040258 | PMID:37990867 | PMID:20554030 | PMID:34930951 | PMID:20551058,10.1186/s40478-023-01525-w | 10.1038/s41467-022-30466-6 | 10.1172/JCI176748 | 10.1126/sciadv.abo5442 | 10.1038/s41586-021-03580-6 | 10.1242/dmm.049861 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/s41536-021-00195-3 | 10.1158/0008-5472.CAN-09-3769,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | Iba1 (019-19741, Thermo Fisher Scientific) | IBA1 (rabbit; Wako Chemicals, 019-19741), CD3 (rat; Bio-Rad, MCA1477) | rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4) | Cells were next stained with anti-IBA1 antibody (Table S1) in TBS containing 5% donkey serum overnight | Wako (rabbit anti-IBA-1) | CD45-PE, IBA1-FITC (immune cell marker) | Wako (IBA-1)",0.95,Accept,Experimental Usage
,SOX10,Unknown,Unknown,,,Human,,SOX10,PMID:38907342 | PMID:37770931 | PMID:35589737 | PMID:35945463 | PMID:38216587 | PMID:29438698 | PMID:38744290 | PMID:38216572 | PMID:36598417 | PMID:39415595,10.1186/s40478-024-01821-z | 10.1186/s40478-023-01639-1 | 10.1038/s41467-022-30466-6 | 10.1007/s00401-022-02478-5 | 10.1038/s41467-023-40408-5 | 10.1016/j.ccell.2018.01.005 | 10.1016/j.crmeth.2024.100772 | 10.1038/s41467-024-44755-9 | 10.1158/2159-8290.CD-22-0786 | 10.1242/dmm.050862,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas. | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.",,"SOX10 at 1:500 dilution (abcam Cat # ab155279) for Schwann cells | SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit) | serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2 | SOX10 (Cell Marque, clone EP268, dilution 1:250, ER2 antigen retrieval) | labeled with primary antibodies including SOX10 to mark schwannoma cells (API 3099, Biocare; labeling validated in schwannoma and melanoma) | Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P) | SOX10 Biocare Medical CAT#ACI3099A | SOX10 (Cell Marque, #383R-1, clone EP268, 1:50 dilution) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10) | Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021)",0.95,Accept,Experimental Usage
,Rbpms,,,,,,,Rbpms,PMID:35589737 | PMID:34930951,10.1038/s41467-022-30466-6 | 10.1038/s41536-021-00195-3,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1 | labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC, RBPMS-APC",0.9,Accept,Experimental Usage
,Tuj-1,,,,,,,Tuj-1,PMID:35589737 | PMID:23328114 | PMID:25772366,10.1038/s41467-022-30466-6 | 10.18632/oncotarget.793 | 10.1016/j.celrep.2015.02.041,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1 | Tuj1 (Covance) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.9,Accept,Experimental Usage
,Peripherin,,,,,,,Peripherin,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"DRG neurons: Peripherin, ISL1, Tuj-1",0.9,Accept,Experimental Usage
,ISL1,,,,,,,ISL1,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,"DRG neurons: Peripherin, ISL1, Tuj-1",0.9,Accept,Experimental Usage
,P-cadherin,Unknown,Unknown,,,,,P-cadherin,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"The primary antibodies used in this study were P-cadherin (R&D Systems, AF761), DCT (PEP8h; gift from Dr. Vincent Hearing)",0.9,Accept,Experimental Usage
,DCT,Unknown,Monoclonal,,,,,DCT,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"DCT (PEP8h; gift from Dr. Vincent Hearing, National Institutes of Health)",0.9,Accept,Experimental Usage
,K14,Unknown,Monoclonal,,,,Biotin,K14,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",0.9,Accept,Experimental Usage
,LacZ,Unknown,Unknown,,,,,LacZ,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)",0.9,Accept,Experimental Usage
,GFP/YFP,Unknown,Unknown,,,,,GFP/YFP,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P)",0.9,Accept,Experimental Usage
,Krox20,Unknown,Unknown,,,,,Krox20,PMID:28465357 | PMID:29438698,10.1101/gad.298703.117 | 10.1016/j.ccell.2018.01.005,Identification of hair shaft progenitors that create a niche for hair pigmentation. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074) | Krox20 (Rabbit; Covance, PRB-236P), MBP (Goat; Santa Cruz Biotechnology, sc-13914)",0.9,Accept,Experimental Usage
,KIT,Unknown,Unknown,,,,,KIT,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,"Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074). For immunofluorescent staining",0.9,Accept,Experimental Usage
,neurofibromin,,Unknown,,,,,neurofibromin,PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"neurofibromin – Bethyl (Bethyl, Cat# A300-140A, primary 1:500, secondary 1:2000) | H12 (Santa Cruz Biotechnology, Cat# sc-376886, primary 1:500, secondary 1:2000) | iNF-07E (gifted by iNFiXion Bioscience, Biointron, Cat# B21900201, primary 1:500, secondary 1:2000) | incubated overnight with the primary anti-neurofibromin antibody (abcam, ab17963, 1/1000) | Antibody against neurofibromin (cat. no. ab17963) was purchased from Abcam | Blots were probed overnight at 4 °C with either the neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S; Danvers, MA, USA) | neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67), P53 (Rabbit, Cell Signaling Technology, #9282) | anti-neurofibromin (#A300; Bethyl Laboratories, Montgomery, TX, USA) | Anti-neurofibromin antibody primary WB CST",0.95,Accept,Experimental Usage
,pERα S118,,Unknown,,,,,pERα S118,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pERα S118 (Sigma, Cat# SAB450399)",0.9,Accept,Experimental Usage
,pERK T202/Y204,,Unknown,,,,,pERK T202/Y204,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)",0.9,Accept,Experimental Usage
,pAKT S473,,Unknown,,,,,pAKT S473,PMID:38216123 | PMID:24681606,10.1016/j.molmet.2024.101876 | 10.18632/oncotarget.1609,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,"pAKT S473 (Cell Signaling Technology, Cat#9271L) | The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100)",0.9,Accept,Experimental Usage
,β-tubulin,Mouse,Unknown,,,,,β-tubulin,PMID:33078583 | PMID:38216123 | PMID:39129390 | PMID:34257279 | PMID:18367665,10.1002/jcsm.12632 | 10.1016/j.molmet.2024.101876 | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1124/jpet.107.135830,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"mouse anti-β-tubulin (Sigma-Aldrich T8328) | β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000) | anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1 : 10 000) | anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000) | β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)",0.95,Accept,Experimental Usage
,BRN3A,Mouse,Monoclonal,,,,,BRN3A,PMID:34040258 | PMID:34930951,10.1038/s41586-021-03580-6 | 10.1038/s41536-021-00195-3,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718) | labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC",0.9,Accept,Experimental Usage
,Thy1.1,,,,,,APC,Thy1.1,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,Thy1.1-APC (ganglion cell marker),0.85,Accept,Experimental Usage
,Caspase9,,,,,,FITC,Caspase9,PMID:34930951 | PMID:23328114,10.1038/s41536-021-00195-3 | 10.18632/oncotarget.793,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Caspase9-FITC (apoptosis marker) | caspase 9 (Cell Signalling),0.85,Accept,Experimental Usage
,Cmyc,,,,,,FITC,Cmyc,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Cmyc-FITC, Oct4-APC (stemness markers)",0.85,Accept,Experimental Usage
,Oct4,,,,,,APC,Oct4,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Cmyc-FITC, Oct4-APC (stemness markers)",0.85,Accept,Experimental Usage
,NeuN,Mouse,Unknown,,,Mouse,Non-conjugated,NeuN,PMID:36890585 | PMID:25535838 | PMID:34930951 | PMID:36241865,10.1186/s40478-023-01525-w | 10.7554/eLife.05151 | 10.1038/s41536-021-00195-3 | 10.1038/s12276-022-00850-9,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"mouse anti-NeuN targeting neurons (1:00; Synaptic Systems) | NeuN (1:400, mouse, Millipore, Billerica, MA) | NeuN-APC (neuronal marker) | Anti-NeuN antibody primary IF and WB CST",0.9,Accept,Experimental Usage
,CD45,Unknown,Monoclonal,,,Human,Vioblue,CD45,PMID:40217315 | PMID:30479396 | PMID:29941005 | PMID:34010628 | PMID:40684195 | PMID:33356508 | PMID:34930951,10.1186/s13073-025-01462-4 | 10.1038/s41467-018-07452-y | 10.1186/s13023-018-0843-1 | 10.1016/j.stem.2021.04.029 | 10.1186/s40478-025-02075-z | 10.1177/0963689720964383 | 10.1038/s41536-021-00195-3,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C. | CD45 [eBioscience; cat. no. 25-0451-82; 1:100] | ...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA)... | endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 103112) | goat anti-CD45 (1:100; Bio-Techne #AF114) | Foxp3-APC and CD45 (immune response markers) | Every 5th section was stained with CD45-PE, IBA1-FITC (immune cell marker)",0.95,Accept,Experimental Usage
,STEM121,,,,,,FITC,STEM121,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,STEM121-FITC (human cell marker),0.85,Accept,Experimental Usage
,HLA-DR,Unknown,Unknown,,,Human,Percp-cy5.5,HLA-DR,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)",0.9,Accept,Experimental Usage
,CD33,Unknown,Unknown,,,Human,APC,CD33,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"anti-CD33 APC (eBioscience, 0.125 µg/test)",0.9,Accept,Experimental Usage
,CD11b,Unknown,Unknown,,,Mouse,,CD11b,PMID:30542164 | PMID:38907342 | PMID:41149489 | PMID:36890585 | PMID:28256556,10.1038/s41586-018-0774-y | 10.1186/s40478-024-01821-z | 10.3390/curroncol32100569 | 10.1186/s40478-023-01525-w | 10.1038/srep43315,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.",,"Primary antibody, anti-CD11b (1:8000 dilution; catalogue number ab133357, Abcam) was applied at 36 °C for 40 min. | CD11b at 1:100 dilution (abcam Cat # ab52478) for myeloid cells | anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test) | incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) | anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)",0.95,Accept,Experimental Usage
,CD9,Unknown,Unknown,,,Human,Non-conjugated,CD9,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)",0.9,Accept,Experimental Usage
,CD81,Unknown,Unknown,,,Human,Non-conjugated,CD81,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"CD81 (Proteintech, 66866-1-Ig)",0.9,Accept,Experimental Usage
,TOMM20,Unknown,Polyclonal,,,Human,Non-conjugated,TOMM20,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,"TOMM20 (Proteintech, 11802-1-AP)",0.9,Accept,Experimental Usage
,HSP90,Unknown,Polyclonal,,,Human,Non-conjugated,HSP90,PMID:41149489 | PMID:27956228,10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"HSP90 (Proteintech, 13171-1-AP) | 1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)",0.9,Accept,Experimental Usage
,AKT,,,,,,,AKT,PMID:36730269 | PMID:41149489 | PMID:33273014 | PMID:29847659 | PMID:20554030 | PMID:26219339 | PMID:21072183 | PMID:18483311 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1074/jbc.RA120.014960 | 10.1167/iovs.17-22588 | 10.1016/j.jneuroim.2010.05.002 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791 | 10.1158/1535-7163.MCT-07-2335 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"total AKT (Catalogue # 4691) | AKT (CST, #9272S, Danvers, MA, USA) | Antibodies recognizing... Akt T308, Akt, p70S6K T389... were from Cell Signaling | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT) | Akt, phospho-NDRG1 (T346), SGK1 | The antibodies used in this study include... Akt... (Cell Signaling Technology) | Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology | total AKT (Cell Signaling Technologies, # 4685, 1:1000 dilution) | Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.95,Accept,Experimental Usage
,pAKT,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,pAKT,PMID:33442015 | PMID:36730269 | PMID:41149489 | PMID:38216572 | PMID:24371224 | PMID:32419643,10.1038/s41591-020-01193-6 | 10.1371/journal.pone.0277305 | 10.3390/curroncol32100569 | 10.1038/s41467-024-44755-9 | 10.1158/0008-5472.CAN-13-2062 | 10.1177/1533033820919759,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology) | pAKT (Catalogue # 4060) | p-AKT (CST, #4051S) | pAKT (Cell Signaling Technologies, #4060, 1:1000 dilution) | Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.95,Accept,Experimental Usage
,ERK,,,,,,,ERK,PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:38714355 | PMID:38216572 | PMID:18413802,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41467-024-44755-9 | 10.1158/1535-7163.MCT-07-0518,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"total ERK (Catalogue # 9102) | total ERK (Cell Signaling cat# 9102 1:1000) | ERK (CST, #4695) | total ERK (rabbit, CST 9102, Danvers, MA USA, 1 : 1000) | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | total ERK (rabbit, CST 9102, 1:1000) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | total ERK (Cell Signaling Technologies, #4695, 1:1000 dilution) | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.95,Accept,Experimental Usage
,p-Erk,Rabbit,Unknown,,,,,p-Erk,PMID:32699356 | PMID:36730269 | PMID:41564118 | PMID:41149489 | PMID:27956228 | PMID:24509877 | PMID:24681606 | PMID:28166733 | PMID:40684195 | PMID:38216572 | PMID:37246765 | PMID:24371224 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3390/curroncol32100569 | 10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.18632/oncotarget.1609 | 10.1186/s12864-017-3519-7 | 10.1186/s40478-025-02075-z | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1158/0008-5472.CAN-13-2062 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90. | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling) | The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370) | p-ERK (Cell Signaling cat# 9101 1:1000) | p-ERK (CST, #9101S) | 1:1000 anti-pErk (Cell Signaling) | Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus) | p-ERK (Cell Signaling 1:1000) | p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C) | rabbit anti-P-ERK (1:250; Cell Signaling #9101) | pERK (Cell Signaling Technologies, #4370, 1:1000 dilution) | H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies) | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz | p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA)",0.95,Accept,Experimental Usage
,ERK1/2,Rabbit,Polyclonal,,,,,ERK1/2,PMID:41022755 | PMID:40590220 | PMID:21072183 | PMID:29670214 | PMID:37681415 | PMID:25043591 | PMID:20200958 | PMID:24375753,10.1038/s41467-025-63619-4 | 10.1172/JCI188932 | 10.1371/journal.pone.0013791 | 10.1038/s41598-018-24310-5 | 10.1172/jci.insight.168445 | 10.1002/jbmr.2316 | 10.1002/jbmr.42 | 10.1002/ana.24093,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Restoring functional neurofibromin by protein transduction. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"anti-ERK1/2 (p44/42 MAPK) antibody (#9102) | ERK1/2 (9102, Cell Signaling Technology) | The antibodies used in this study include... Erk1/2... (Cell Signaling Technology) | Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000) | ERK1/2 (CST 9107, clone 3A7) | ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000) | Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies | pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",0.95,Accept,Experimental Usage
,phospho-ERK1/2,Rabbit,Polyclonal,,,,,phospho-ERK1/2,PMID:41022755 | PMID:24932921 | PMID:33436083 | PMID:33934112 | PMID:29670214 | PMID:25043591 | PMID:20200958,10.1038/s41467-025-63619-4 | 10.1002/jbmr.2298 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03716-6 | 10.1038/s41598-018-24310-5 | 10.1002/jbmr.2316 | 10.1002/jbmr.42,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Restoring functional neurofibromin by protein transduction. | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,"rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101) | The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA) | phospho-ERK1/2 (Cell Signaling #9101) | rabbit polyclonal anti-phospho-ERK1/2 was from Cell Signaling (Cat. #9101) | anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000) | using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000) | Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies",0.95,Accept,Experimental Usage
,Flag,Unknown,Unknown,,,,,Flag,PMID:40590220 | PMID:36420221 | PMID:31836666 | PMID:24595234 | PMID:36689660 | PMID:40225167 | PMID:16835260,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.1074/jbc.RA119.010934 | 10.1371/journal.pone.0090853 | 10.1073/pnas.2208960120 | 10.1155/2023/9628049 | 10.1093/hmg/ddl165,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Flag (F7425, MilliporeSigma) | Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO) | Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793) | Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000 | Supernatants from cleared lysates were incubated with Anti-FLAG M2 affinity gel (Sigma) to immunoprecipitated FLAG-tagged protein complexes | Primary antibodies used were FLAG-M2 and KRAS (Sigma) | Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences | equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)",0.95,Accept,Experimental Usage
,V5,Rabbit,Unknown,,,,,V5,PMID:31836666 | PMID:40225167,10.1074/jbc.RA119.010934 | 10.1155/2023/9628049,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were V5 (rabbit, 13202) | Invitrogen (mouse anti-V5), Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)",0.9,Accept,Experimental Usage
,HA,Mouse,Monoclonal,,,,,HA,PMID:41022755 | PMID:31836666 | PMID:40225167 | PMID:36689660,10.1038/s41467-025-63619-4 | 10.1074/jbc.RA119.010934 | 10.1155/2023/9628049 | 10.1073/pnas.2208960120,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"mouse anti-HA antibody (26183) was purchased from Invitrogen | Primary antibodies (Cell Signaling Technology) used for Western blotting were HA (rabbit, 3724) | Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc) | HA, HSP70, and Ubiquitin (Cell Signaling)",0.95,Accept,Experimental Usage
,pEGFR,,Unknown,,,,,pEGFR,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Western blots to verify protein expression levels were run on Tris acetate or Bolt gels and probed with a series of antibodies: pEGFR (Cell Signaling 3777),0.9,Accept,Experimental Usage
,Vinculin,,,,,,,Vinculin,PMID:36730269 | PMID:31836666 | PMID:38502231 | PMID:37164978 | PMID:38481529 | PMID:38127282 | PMID:33658640 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1074/jbc.RA119.010934 | 10.1172/JCI176748 | 10.1038/s41467-023-38432-6 | 10.3389/fcell.2024.1359561 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41416-021-01270-8 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"Vinculin (Catalogue # 4650) | vinculin (Cell Signaling 19301) | vinculin (4650S, Cell Signaling Technology) | Vinculin(1:30000, Cat #V9264, Sigma Aldrich) | anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading | Vinculin (ab219649, 1:1000 dilution, Abcam) | Vinculin (mouse, V284, Sigma, St. Louis, MO, USA) | GST and Vinculin (Bethyl Laboratories)",0.95,Accept,Experimental Usage
,KRAS,,Monoclonal,,,,,KRAS,PMID:31836666 | PMID:37681415 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1172/jci.insight.168445 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1) | KRAS (Sigma; WH0003845M1, clone 3B10-2F2; does not detect proteins with E162L mutation) | Primary antibodies used were FLAG-M2 and KRAS (Sigma)",0.9,Accept,Experimental Usage
,collagen IV,Unknown,Unknown,,,,,collagen IV,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500),0.95,Accept,Experimental Usage
,MyHC type 1,Mouse,Monoclonal,,,,,MyHC type 1,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500),0.95,Accept,Experimental Usage
,MyHC type 2A,Mouse,Monoclonal,,,,,MyHC type 2A,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200),0.95,Accept,Experimental Usage
,laminin,Rabbit,Unknown,,,,,laminin,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500),0.95,Accept,Experimental Usage
,Pax7,Mouse,Monoclonal,,,,,Pax7,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-Pax7 (DSHB Pax7; 1:10),0.95,Accept,Experimental Usage
,myosin heavy chain,Mouse,Unknown,,,,,myosin heavy chain,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000),0.95,Accept,Experimental Usage
,beta III tubulin,Unknown,Unknown,,,,,beta III tubulin,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500),0.95,Accept,Experimental Usage
,perilipin A/B,Unknown,Unknown,,,,,perilipin A/B,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250),0.95,Accept,Experimental Usage
,PPARG,Rabbit,Unknown,,,,,PPARG,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443),0.95,Accept,Experimental Usage
,phosphor (pThr172) AMPKa,Rabbit,Unknown,,,,,phosphor (pThr172) AMPKa,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),0.95,Accept,Experimental Usage
,AMPKα,Rabbit,Unknown,,,,,AMPKα,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-AMPKα (Cell Signaling Technology 2532),0.95,Accept,Experimental Usage
,β-actin,Mouse,Unknown,,,,,β-actin,PMID:33078583 | PMID:38201517 | PMID:41022755 | PMID:18451155 | PMID:32438526 | PMID:32457840 | PMID:24509877 | PMID:34040258 | PMID:33436083 | PMID:34011935 | PMID:41036607 | PMID:21072183 | PMID:26904939 | PMID:33934112 | PMID:20049725 | PMID:24371224 | PMID:23328114 | PMID:30274821 | PMID:32419643,10.1002/jcsm.12632 | 10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/0008-5472.CAN-07-6867 | 10.1002/lary.28671 | 10.3389/fonc.2020.00687 | 10.1038/onc.2013.506 | 10.1038/s41586-021-03580-6 | 10.1186/s13072-020-00380-6 | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-24-1053 | 10.1371/journal.pone.0013791 | 10.1016/j.celrep.2016.01.074 | 10.1038/s41419-021-03716-6 | 10.1002/emmm.200900027 | 10.1158/0008-5472.CAN-13-2062 | 10.18632/oncotarget.793 | 10.1016/j.ebiom.2018.09.042 | 10.1177/1533033820919759,"Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.",,"mouse anti-β-actin (Cell Signaling Technology 58169) | β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441). | The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology | Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma) | The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316) | Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich | p473AKT, AKT, and β-ACTIN (Cell Signaling) as a loading control | rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15 | β-Actin (Cell Signaling #3700) | Antibodies used in western blotting targeting β-actin (#13E5) | β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172) | The antibodies used in this study include... β-actin (Sigma) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA) | mouse monoclonal anti-β actin was from Santa Cruz (Cat. #sc-47778) | then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz | β-actin (Sigma) | The β-actin antibody (# AA128, Beyotime) was used to ensure equal loading of total protein | The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)",0.95,Accept,Experimental Usage
,phosphor (s235/236) S6,Rabbit,Unknown,,,,,phosphor (s235/236) S6,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),0.95,Accept,Experimental Usage
,MyHC type 2B,Mouse,Monoclonal,,,,,MyHC type 2B,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,mouse anti-MyHC type 2B (DSHB BF-F3),0.95,Accept,Experimental Usage
,phosphor (Ser473) AKT,Rabbit,Unknown,,,,,phosphor (Ser473) AKT,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)",0.95,Accept,Experimental Usage
,phospho (Ser1101) IRS-1,Rabbit,Unknown,,,,,phospho (Ser1101) IRS-1,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)",0.95,Accept,Experimental Usage
,phospho (Ser636/639) IRS-1,Rabbit,Unknown,,,,,phospho (Ser636/639) IRS-1,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)",0.95,Accept,Experimental Usage
,DIG-Fab,Unknown,Unknown,,,,alkaline phosphatase,DIG-Fab,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)",0.95,Accept,Experimental Usage
,RAS,Mouse,Monoclonal,,,,,RAS,PMID:38201517 | PMID:18367665 | PMID:18413802 | PMID:36689660,10.3390/cancers16010089 | 10.1124/jpet.107.135830 | 10.1158/1535-7163.MCT-07-0518 | 10.1073/pnas.2208960120,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002). | Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA) | Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody | pan-RAS (Abcam)",0.95,Accept,Experimental Usage
,N-RAS,Rabbit,Polyclonal,,,,,N-RAS,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519).",0.95,Accept,Experimental Usage
,RAB5A,Rabbit,Polyclonal,,,,,RAB5A,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309).",0.95,Accept,Experimental Usage
,RAP1A,Unknown,Polyclonal,,,,,RAP1A,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482).",0.95,Accept,Experimental Usage
,GAPDH,Rabbit,Polyclonal,,,,,GAPDH,PMID:38201517 | PMID:33442015 | PMID:32383545 | PMID:23175151 | PMID:37446790 | PMID:32461556 | PMID:33273014 | PMID:38502231 | PMID:39129390 | PMID:28126595 | PMID:23535903 | PMID:24681606 | PMID:34065204 | PMID:23685747 | PMID:26219339 | PMID:38714355 | PMID:36148553 | PMID:38203448 | PMID:24824755 | PMID:29847659 | PMID:29670214 | PMID:25043298 | PMID:36241865,10.3390/cancers16010089 | 10.1038/s41591-020-01193-6 | 10.15252/embr.201949117 | 10.1038/bjc.2012.518 | 10.3390/molecules28135128 | 10.1038/s41467-020-16432-0 | 10.1074/jbc.RA120.014960 | 10.1172/JCI176748 | 10.1002/1878-0261.13704 | 10.1016/j.ebiom.2017.01.020 | 10.1158/2159-8290.CD-13-0081 | 10.18632/oncotarget.1609 | 10.3390/ijms22105367 | 10.1038/ng.2641 | 10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-23-0510 | 10.1093/brain/awac342 | 10.3390/ijms25010277 | 10.1371/journal.pone.0096733 | 10.1167/iovs.17-22588 | 10.1038/s41598-018-24310-5 | 10.1038/onc.2014.185 | 10.1038/s12276-022-00850-9,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Restoring functional neurofibromin by protein transduction. | Oncogenic role of Merlin/NF2 in glioblastoma. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.",,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118). | pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology) | anti‐GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam) | GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc.) | Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology | GAPDH (LN2100751, 1:1000, Labned) | Other antibodies included... and GAPDH (EMD Millipore) | GAPDH (SC-32233, Santa Cruz Biotechnology) | GAPDH (rabbit, Proteintech 10 494‐1‐AP, San Diego, CA USA, 1 : 15 000) | PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore | The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling) | GAPDH (Cell Signaling 1:2000) | human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam | probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.) | GAPDH (EMD Millipore) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | GAPDH (1:5000; AB2302; Merck) | The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA) | GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA) | and anti-GAPDH (Novus, Littleton, CO, USA) | anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000 | Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling) | Anti-GAPDH antibody primary WB CST",0.95,Accept,Experimental Usage
,MYF-4,,Unknown,,,,,MYF-4,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)",0.85,Accept,Experimental Usage
,S100,Unknown,Unknown,,,,,S100,PMID:24040940 | PMID:25851896 | PMID:30479396 | PMID:24681606 | PMID:40025578 | PMID:30055648 | PMID:18636037 | PMID:38744290 | PMID:36148553 | PMID:33356508 | PMID:41001593 | PMID:33591953 | PMID:36598417 | PMID:21111000 | PMID:33767727 | PMID:15255999 | PMID:15240917 | PMID:19144871,10.1186/1479-5876-11-213 | 10.3988/jcn.2015.11.2.172 | 10.1038/s41467-018-07452-y | 10.18632/oncotarget.1609 | 10.1186/s40478-025-01965-6 | 10.1186/s13104-018-3630-0 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.crmeth.2024.100772 | 10.1093/brain/awac342 | 10.1177/0963689720964383 | 10.1080/23723556.2025.2561292 | 10.1172/jci.insight.146351 | 10.1158/2159-8290.CD-22-0786 | 10.1016/j.jneumeth.2010.10.021 | 10.3389/fgene.2021.603195 | 10.1186/1476-4598-3-20 | 10.1155/S1110724304308107 | 10.3181/0809-RM-275,"Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Chromosome 8 gain is associated with high-grade transformation in MPNST. | Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. | A novel imaging-compatible sciatic nerve schwannoma model. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing. | Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. | Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.",,"incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution | cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark) | S100 (DAKO, Z0311, 1:5000) | primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200)) | rabbit anti-human S100 (ZSGB-BIO, ZA-0225) | antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9) to demonstrate human Schwann cell origin | rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO) | S100 Biocare Medical CAT#ACI3237A | S100 (pre-diluted; GA504; Dako) | incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells) | S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000 | IHC was performed using the Avidin/Biotin blocking kit (Vector Labs, SP-2001) staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam) | FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10) | S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry | Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei | They were all S100-positive by immunostaining. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining | Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif) | The following primary antibodies were used: rabbit anti-NF2 (Santa Cruz); mouse anti-p55 monoclonal (this study); mouse anti-S100 (SIGMA)",0.95,Accept,Experimental Usage
,HMB45,,Unknown,,,,,HMB45,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,0.85,Accept,Experimental Usage
,Melan-A,,Unknown,,,,,Melan-A,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma,0.85,Accept,Experimental Usage
,CD90,Mouse,Monoclonal,,,Human,PECy5,CD90,PMID:29941005 | PMID:25851896,10.1186/s13023-018-0843-1 | 10.3988/jcn.2015.11.2.172,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend)... | cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany)",0.9,Accept,Experimental Usage
,S100B,Rabbit,Polyclonal,,,,,S100B,PMID:41022755 | PMID:38175707 | PMID:41444363 | PMID:38216572 | PMID:37246765 | PMID:39110684 | PMID:34646065,10.1038/s41467-025-63619-4 | 10.1172/jci.insight.168826 | 10.1038/s41598-025-32031-9 | 10.1038/s41467-024-44755-9 | 10.1093/neuonc/noad097 | 10.1371/journal.pone.0308207 | 10.1155/2021/9386823,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers. | Survival and,,"rabbit anti-S100B antibody (Z0311) was purchased from DAKO | incubated with primary antibodies, p75 (1:100, Ab3125, Abcam), S100B (1:1,000, Z0311, Dako) | Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein | S100B (Ventana, #760-2523, 1:2 dilution) | Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology) | Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio | immunohistochemical S100 B data from a pathology service...An S100 B immunonegative tumor phenotype was associated with a significantly worse outcome",0.95,Accept,Experimental Usage
,HMGA2,Unknown,Unknown,,,,,HMGA2,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage
,beta-Catenin,Unknown,Unknown,,,,,beta-Catenin,PMID:27956228 | PMID:24371224,10.1053/j.gastro.2016.12.002 | 10.1158/0008-5472.CAN-13-2062,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.9,Accept,Experimental Usage
,CK19,Unknown,Unknown,,,,,CK19,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)",0.9,Accept,Experimental Usage
,SOX9,Unknown,Unknown,,,,,SOX9,PMID:27956228 | PMID:24509877 | PMID:20049725 | PMID:32396062,10.1053/j.gastro.2016.12.002 | 10.1038/onc.2013.506 | 10.1002/emmm.200900027 | 10.7554/eLife.55137,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences) | Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako) | probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700) | We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK) | Antibody anti-SOX9, rabbit polyclonal Millipore Sigma Cat. # AB5535 RRID: AB_2239761 1/500 dilution",0.9,Accept,Experimental Usage
,Merlin,Rabbit,Polyclonal,,,,,Merlin,PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,"rabbit anti-GAPDH, rabbit anti-Histone 3, rabbit anti-Merlin, mouse anti-p53, mouse anti-Ki67, and rabbit anti-β-catenin, all from Cell Signaling | Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) | The antibodies used in this study include... Merlin (Cell Signaling Technology) | Anti-Merlin monoclonal antibody 4B5 was made by W. Ip | The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology | anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz | anti-Merlin (clone A-19 and C-18, 1:50, Santa Cruz Biotechnology, Heidelberg, Germany; or HPA003097, 1:100, Atlas Antibodies | polyclonal anti-merlin (1:250, Santa Cruz) | Immunoblotting analysis was performed with antibodies specific for merlin (# HPA003097, Sigma-Aldrich | Subsequently, the blot was incubated with a 1:1000 dilution of anti-merlin antibody overnight at 4°C | The absence of merlin in schwannoma cells was confirmed regularly by Western blot (1:2000, Cat. No. 12888, Cell Signaling Technology) | guinea-pig anti-Merlin [8] was used at 1∶5000",0.95,Accept,Experimental Usage
,collagen XV,,Polyclonal,,,,,collagen XV,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000)...",0.95,Accept,Experimental Usage
,collagen XVIII,,Monoclonal,,,,,collagen XVIII,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody...",0.95,Accept,Experimental Usage
,K1,Unknown,Unknown,,,,,K1,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"K1 (BioLegend, 905601, 1:100)",0.9,Accept,Experimental Usage
,NF1,Rabbit,Polyclonal,,,,,NF1,PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Rabbit anti-NF1 antibody (A300-140A) was purchased from Bethyl Laboratories | anti-NF1 D7R7D #14624 (Cell Signaling, rabbit, 2% BSA, 1:1000, overnight, 4 °C) | NF1 (A300–140A) was obtained from Bethyl | We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience) | Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000) | NF1 (Santa Cruz; sc-67, 1:100) | NF1 (Santa Cruz; H-12, 1:100) | Western blotting and an antibody specific for NF1 (Abcam, Cambridge, United Kingdom; ab238142) | Immunoprecipitations were performed using 400 µg of total protein in 1 ml IP buffer incubated with 200 μl of mAb21 anti-Nf1 monoclonal antibody supernatant | NF1 (#D7R7D) | Nf1 (1:1000, rabbit, Upstate, Lake Placid, NY)",0.95,Accept,Experimental Usage
,LUMICAN,Unknown,Unknown,,,,,LUMICAN,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,"LUMICAN (Santa Cruz; sc-166871, 1:200)",0.9,Accept,Experimental Usage
,CD3,Unknown,Monoclonal,,,Mouse,,CD3,PMID:30542164 | PMID:30479396 | PMID:38502231 | PMID:30531922 | PMID:36322658 | PMID:38216587 | PMID:39321200 | PMID:37410426,10.1038/s41586-018-0774-y | 10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1038/s41591-018-0263-8 | 10.1126/sciadv.abo5442 | 10.1038/s41467-023-40408-5 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell. | precoated with indicated doses of anti-CD3 Ab (eBioscience; cat. no. 16-0031-86) | CD3 (ab16669, Abcam) | Primary antibodies were incubated at 4 °C overnight: CD3 (Dako, A0452, 1:200) | CD3 (rat; Bio-Rad, MCA1477), GLUT1 (rabbit; Abcam, ab652) | slides were subjected to antigen retrieval and labeled with CD3 (A0452, Agilent Technologies, Santa Clara, CA; labeling validated by over-expression) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3... | CD3 to identify T cells (rabbit monoclonal, NeoMarkers Company, #RM-9107-S, 1:200)",0.95,Accept,Experimental Usage
,CD28,Unknown,Monoclonal,,,,,CD28,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),0.9,Accept,Experimental Usage
,CD69,Unknown,Monoclonal,,,,FITC,CD69,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85; 1:100),0.9,Accept,Experimental Usage
,CD4,Unknown,Unknown,,,,,CD4,PMID:30479396 | PMID:38502231 | PMID:40025578,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1186/s40478-025-01965-6,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD4 [eBioscience; cat. no. 17-0042-83; 1:100] | CD4 (ab183685, Abcam) | HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",0.9,Accept,Experimental Usage
,CD8,Unknown,Unknown,,,,,CD8,PMID:30479396 | PMID:30531922 | PMID:34040258 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1038/s41591-018-0263-8 | 10.1038/s41586-021-03580-6 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"CD8 [Lifetech; cat. no. A15836; 1:100] | CD8 (Leica NCL-L-CD8–4B11, 1:200) | rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,FoxP3,Unknown,Unknown,,,,,FoxP3,PMID:30479396 | PMID:38502231 | PMID:33356508 | PMID:39321200,10.1038/s41467-018-07452-y | 10.1172/JCI176748 | 10.1177/0963689720964383 | 10.1158/1078-0432.CCR-24-1454,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"FoxP3 [eBioscience; cat. no. 12-57773-80; 1:100] | Foxp3 (ab215206, Abcam) | Foxp3-APC and CD45 (immune response markers) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,B220,Unknown,Unknown,,,,,B220,PMID:30479396 | PMID:37410426,10.1038/s41467-018-07452-y | 10.1158/1078-0432.CCR-23-0749,"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"B220 [eBioscience; cat. no. 11-0452-85; 1:100] | B220 to identify B cells (RRID: AB_323211, rat anti-mouse monoclonal, Serotec Company, Catalog #MCA1258G, 1:1200)",0.9,Accept,Experimental Usage
,MIA,Unknown,Monoclonal,,,Human,,MIA,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,"stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40",0.9,Accept,Experimental Usage
,AQP4,Unknown,Unknown,,,,,AQP4,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage
,NG2,,,,,,,NG2,PMID:36730269 | PMID:19191334,10.1371/journal.pone.0277305 | 10.1002/glia.20845,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"NG2 (Catalogue # PA5-17199) from Invitrogen | AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.95,Accept,Experimental Usage
,O4,Unknown,Unknown,,,,,O4,PMID:19191334 | PMID:25772366,10.1002/glia.20845 | 10.1016/j.celrep.2015.02.041,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA) | cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)",0.9,Accept,Experimental Usage
,LHX2,Unknown,Unknown,,,,,LHX2,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)",0.9,Accept,Experimental Usage
,APC,Unknown,Unknown,,,,,APC,PMID:19191334 | PMID:37164978,10.1002/glia.20845 | 10.1038/s41467-023-38432-6,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"APC (Calbiochem; San Diego, CA) | APC(1:500, Cat #15270, Abcam)",0.9,Accept,Experimental Usage
,FOXG1,Unknown,Unknown,,,,,FOXG1,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage
,FOXP2,Unknown,Unknown,,,,,FOXP2,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage
,HOXB3,Unknown,Unknown,,,,,HOXB3,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)",0.9,Accept,Experimental Usage
,GLAST,Unknown,Unknown,,,,,GLAST,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,GLAST (a gift from Dr. Watanabe; (Shibata et al. 1997)),0.85,Accept,Experimental Usage
,NF1GRP-D,Rabbit,Unknown,,,,,NF1GRP-D,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,"Rabbit anti-NF1GRP-D (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:200 dilution to detect neurofibromin expression",0.9,Accept,Experimental Usage
,α-tubulin,Unknown,Unknown,,,,,α-tubulin,PMID:19191334 | PMID:32642733 | PMID:38203448 | PMID:21216928,10.1002/glia.20845 | 10.1093/noajnl/vdz061 | 10.3390/ijms25010277 | 10.1158/1535-7163.MCT-10-0654,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis | anti-α-tubulin (Sigma-Aldrich) | anti-α-tubulin-Alexa488 antibody (Life Technologies) | anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA) | using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization",0.9,Accept,Experimental Usage
,DDK tag,Unknown,Unknown,,,,,DDK tag,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,The expression of the DDK-tagged transcript was validated by Western blot using anti-DDK antibodies,0.85,Accept,Experimental Usage
,RFP,Unknown,Unknown,,,,HRP,RFP,PMID:31015291 | PMID:40684195,10.1126/scisignal.aau8749 | 10.1186/s40478-025-02075-z,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,specific for RFP (cat no. ab34767) was from Abcam | rabbit anti-RFP (1:1000; Rockland #600-401-379),0.9,Accept,Experimental Usage
,YAP1,Unknown,Unknown,,,,,YAP1,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,Antibody specific for YAP1 was from Cell Signaling Inc.,0.85,Accept,Experimental Usage
,MYC,,,,,,,MYC,PMID:36730269 | PMID:40225167,10.1371/journal.pone.0277305 | 10.1155/2023/9628049,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,"MYC (Catalogue # 18583) | Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)",0.95,Accept,Experimental Usage
,phosphorylated ERK Thr202/Tyr204,Unknown,Unknown,,,,,phosphorylated ERK Thr202/Tyr204,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage
,phosphorylated Akt Ser473,Unknown,Unknown,,,,,phosphorylated Akt Ser473,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage
,phosphorylated S6 Ser235/236,Unknown,Unknown,,,,,phosphorylated S6 Ser235/236,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)",0.9,Accept,Experimental Usage
,γH2AX Ser139,Unknown,Unknown,,,,,γH2AX Ser139,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,"Coverslips were permeabilized and probed with anti-γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody",0.9,Accept,Experimental Usage
,HIF1α,Rabbit,Polyclonal,,,,,HIF1α,PMID:33934112 | PMID:35393510 | PMID:33658640 | PMID:24824755,10.1038/s41419-021-03716-6 | 10.1038/s41418-022-00991-4 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"rabbit polyclonal anti-HIF1α was from Novus Biologicals (Cat. #NB100-449) | rabbit polyclonal anti-HIF1α was from GeneTex (Cat. #GTX131826) | IHC was performed using a primary rabbit polyclonal anti HIF1α antibody (Novus Biologicals, Centennials, CO, USA) | HIF1-α (rabbit, GTX127309, GeneTex, Irvine, CA, USA) | HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",0.9,Accept,Experimental Usage
,BNIP3,Unknown,Unknown,,,,,BNIP3,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"BNIP3 (Sigma, St. Louis, MO)",0.85,Accept,Experimental Usage
,BECLIN1,Unknown,Unknown,,,,,BECLIN1,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)",0.85,Accept,Experimental Usage
,LC3,Unknown,Unknown,,,,,LC3,PMID:38203448 | PMID:24824755,10.3390/ijms25010277 | 10.1371/journal.pone.0096733,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA) | LC3 (Abgent, San Diego, CA)",0.9,Accept,Experimental Usage
,p53,Rabbit,Unknown,,,,,p53,PMID:32699356 | PMID:32948135 | PMID:32461556 | PMID:35945463 | PMID:30274821 | PMID:30055648 | PMID:24371224,10.1038/s41467-020-17382-3 | 10.1186/s12885-020-07397-w | 10.1038/s41467-020-16432-0 | 10.1007/s00401-022-02478-5 | 10.1016/j.ebiom.2018.09.042 | 10.1186/s13104-018-3630-0 | 10.1158/0008-5472.CAN-13-2062,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems) | tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO) | probed with antibodies directed against p53 (sc-6243, 1:250, Santa Cruz Biotechnology) | p53 (Biocare, clone DO-7, 1:100 dilution, ER2 antigen retrieval) | p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling) | anti-p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713) | and p53 (1:500, NCL-p53-505, Novocastra) were used",0.95,Accept,Experimental Usage
,Olig2,Rabbit,Unknown,,,,,Olig2,PMID:32699356 | PMID:18451155 | PMID:29715273 | PMID:35945463 | PMID:20554030 | PMID:20551058,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867 | 10.1371/journal.pone.0196726 | 10.1007/s00401-022-02478-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore) | BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz) | Guinea pig anti-Olig2 (1:10000, a kind gift of home-made antibody from Dr. B. Novitch) | anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany) | OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution, ER1 antigen retrieval) | The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles | Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute)",0.95,Accept,Experimental Usage
,Pten,Rabbit,Unknown,,,,,Pten,PMID:32699356 | PMID:18451155,10.1038/s41467-020-17382-3 | 10.1158/0008-5472.CAN-07-6867,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling) | glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience) | Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)",0.95,Accept,Experimental Usage
,p-S6,Rabbit,Unknown,,,,,p-S6,PMID:32699356 | PMID:24509877 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1038/onc.2013.506 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling) | Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus) | p-S6 (1:1000, rabbit, Cell Signaling)",0.95,Accept,Experimental Usage
,BrdU,Unknown,Unknown,,,,,BrdU,PMID:32699356 | PMID:36322658 | PMID:29438698 | PMID:18636037 | PMID:18242513 | PMID:32396062 | PMID:25535838,10.1038/s41467-020-17382-3 | 10.1126/sciadv.abo5442 | 10.1016/j.ccell.2018.01.005 | 10.1097/MAO.0b013e31817f7398 | 10.1016/j.ccr.2008.01.003 | 10.7554/eLife.55137 | 10.7554/eLife.05151,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"rat anti-BrdU (ab6326, 1:500, Abcam) | BrdU (rat; Abcam, ab6326), VEGFA (rabbit; ABclonal, A0280) | BrdU (Rat; Abcam, ab6326), α-SMA (Mouse; Sigma, clone 1A4, A2547) | mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO) | cells were stained for BrdU using a flow-cytometry kit (BD Pharmingen; cat#559619) | Antibody anti-BrdU, rat monoclonal Thermo Fisher Cat. # MA 182088 RRID: AB_927214 1/500 dilution | Antibody anti-BrdU, mouse monoclonal Thermo Fisher Cat. # B35128 RRID: AB_2536432 Clone MoBu-1 | BrdU (1:1000, rat, Abcam, Cambridge, MA)",0.95,Accept,Experimental Usage
,PAX8,Unknown,Unknown,,,,,PAX8,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"PAX8 Proteintech, 10336-1-AP 1:2000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage
,Ac-alpha-Tubulin,Unknown,Unknown,,,,,Ac-alpha-Tubulin,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"Ac-alpha-Tubulin Santa Cruz, sc-23950 1:2000 Overnight, RT Citrate buffer, pH 6.0",0.9,Accept,Experimental Usage
,Cytokeratin-8,Unknown,Unknown,,,,,Cytokeratin-8,PMID:32461556 | PMID:24371224,10.1038/s41467-020-16432-0 | 10.1158/0008-5472.CAN-13-2062,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Cytokeratin-8 Santa Cruz, sc-101459 1:50 Overnight, RT Citrate buffer, pH 6.0 | Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma)",0.9,Accept,Experimental Usage
,γH2A.X,Mouse,Monoclonal,,,,,γH2A.X,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,"mouse anti-γH2A.X primary antibody (1:500, Millipore, clone JBW301)",0.9,Accept,Experimental Usage
,ABCC1,Unknown,Unknown,,,,,ABCC1,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution,0.95,Accept,Experimental Usage
,mCherry,Mouse,Unknown,,,,,mCherry,PMID:34415582 | PMID:20551058,10.1002/glia.24075 | 10.1158/0008-5472.CAN-09-3769,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"Mouse anti-mCherry, Abcam, Cat. # ab125096 (1:500) | Clontech (Dsred (mCherry))",0.95,Accept,Experimental Usage
,glutamine synthetase,Mouse,Monoclonal,,,,,glutamine synthetase,PMID:34415582 | PMID:32396062,10.1002/glia.24075 | 10.7554/eLife.55137,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302 (1/500) | Antibody anti-glutamine synthetase (GS), mouse monoclonal Sigma-Aldrich Cat. # MAB302 RRID: AB_2110656",0.95,Accept,Experimental Usage
,NHE1,Mouse,Monoclonal,,,,,NHE1,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,"mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage
,ERBB3 Y1197,,,,,Human,,ERBB3 Y1197,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",0.9,Accept,Experimental Usage
,ERBB3,,,,,Human,,ERBB3,PMID:33273014 | PMID:20195187,10.1074/jbc.RA120.014960 | 10.1097/MAO.0b013e3181d2777f,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling | polyclonal anti-ErbB3 (1:250; Santa Cruz)",0.9,Accept,Experimental Usage
,EPHA2 S897,,,,,Human,,EPHA2 S897,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling",0.9,Accept,Experimental Usage
,NDRG1 T346,,,,,Human,,NDRG1 T346,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... NDRG1 T346, Akt S473... were from Cell Signaling",0.9,Accept,Experimental Usage
,Akt S473,,,,,Human,,Akt S473,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... NDRG1 T346, Akt S473, Akt T308... were from Cell Signaling",0.9,Accept,Experimental Usage
,Akt T308,,,,,Human,,Akt T308,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... Akt S473, Akt T308, Akt... were from Cell Signaling",0.9,Accept,Experimental Usage
,p70S6K T389,,,,,Human,,p70S6K T389,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... Akt, p70S6K T389, p70S6K... were from Cell Signaling",0.9,Accept,Experimental Usage
,p70S6K,,,,,Human,,p70S6K,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies recognizing... p70S6K T389, p70S6K, ribosomal S6 S240/244... were from Cell Signaling | p70 S6K, phospho-Akt (S473), Akt",0.9,Accept,Experimental Usage
,ribosomal S6 S240/244,,,,,Human,,ribosomal S6 S240/244,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... p70S6K, ribosomal S6 S240/244, S6... were from Cell Signaling",0.9,Accept,Experimental Usage
,S6,,,,,Human,,S6,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies recognizing... ribosomal S6 S240/244, S6, IGF1R Y1135/36/IR Y1150/51... were from Cell Signaling | Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",0.9,Accept,Experimental Usage
,IGF1R Y1135/36/IR Y1150/51,,,,,Human,,IGF1R Y1135/36/IR Y1150/51,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... S6, IGF1R Y1135/36/IR Y1150/51, IGF1R... were from Cell Signaling",0.9,Accept,Experimental Usage
,IGF1R,,,,,Human,,IGF1R,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... IGF1R Y1135/36/IR Y1150/51, IGF1R, FOXO1/3a T24/T32... were from Cell Signaling",0.9,Accept,Experimental Usage
,FOXO1/3a T24/T32,,,,,Human,,FOXO1/3a T24/T32,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... IGF1R, FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",0.9,Accept,Experimental Usage
,FOXO3,,,,,Human,,FOXO3,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,"Antibodies recognizing... FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling",0.9,Accept,Experimental Usage
,EPHA2,,,,,Human,,EPHA2,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included EPHA2 (Santa Cruz),0.9,Accept,Experimental Usage
,secreted form of NRG1,,,,,Human,,secreted form of NRG1,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,Other antibodies included... secreted form of NRG1 (R&D Systems),0.9,Accept,Experimental Usage
,NDRG1,,,,,Human,,NDRG1,PMID:33273014 | PMID:26219339,10.1074/jbc.RA120.014960 | 10.18632/oncotarget.4858,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Other antibodies included... NDRG1 (Abcam) | NDRG1 (Abcam; Cambridge, MA)",0.9,Accept,Experimental Usage
,NF2/merlin,,Polyclonal,,,Human,,NF2/merlin,PMID:33273014 | PMID:38216572 | PMID:19144871,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,"Anti-NF2/merlin polyclonal antibody has been previously described | NF2/Merlin (Abcam, #ab88957, clone AF1G4, 1:2000 dilution) | Another anti-merlin polyclonal antibody (A-19) was purchased from Santa Cruz Biotechnology",0.9,Accept,Experimental Usage
,STING,Unknown,Unknown,,,,,STING,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"STING (13647S, Cell Signaling Technology)",0.9,Accept,Experimental Usage
,TBK1,Unknown,Unknown,,,,,TBK1,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"TBK1 (3504T, Cell Signaling Technology)",0.9,Accept,Experimental Usage
,p-TBK1,Unknown,Unknown,,,,,p-TBK1,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p-TBK1 (s172) (5483T, Cell Signaling Technology)",0.9,Accept,Experimental Usage
,IRF3,Unknown,Unknown,,,,,IRF3,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"IRF3 (MA5-32348, Invitrogen, Thermo Fisher Scientific)",0.9,Accept,Experimental Usage
,p-IRF3,Unknown,Unknown,,,,,p-IRF3,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p-IRF3 (4947S, Cell Signaling Technology)",0.9,Accept,Experimental Usage
,NF-κB,Unknown,Unknown,,,,,NF-κB,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"NF-κB (ab16502, Abcam)",0.9,Accept,Experimental Usage
,p-NF-κB,Unknown,Unknown,,,,,p-NF-κB,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"p–NF-κB (3033S, Cell Signaling Technology)",0.9,Accept,Experimental Usage
,PD-L1,Unknown,Unknown,,,,,PD-L1,PMID:38502231 | PMID:40025578 | PMID:39321200 | PMID:37410426,10.1172/JCI176748 | 10.1186/s40478-025-01965-6 | 10.1158/1078-0432.CCR-24-1454 | 10.1158/1078-0432.CCR-23-0749,"STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"PD-L1 (ab213480, Abcam, 66248-1-Ig, Proteintech) | 100 μg mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell) | rabbit anti-human PDL1 (Genetex, GTX104763) | Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3, human leukocyte antigen (HLA)-class I, and PD-L1 | bi-weekly intraperitoneal injections of 10 mg/kg anti-PDL1 antibody (BioXCell BE0101)",0.9,Accept,Experimental Usage
,CTLA-4,Unknown,Monoclonal,,,,,CTLA-4,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"CTLA-4 (BE0164, Bio X Cell) | 300 μg mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)",0.9,Accept,Experimental Usage
,CD20,Unknown,Unknown,,,,,CD20,PMID:38502231 | PMID:30531922,10.1172/JCI176748 | 10.1038/s41591-018-0263-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"CD20 (BS-0080R, Bioss) | CD20 (Leica, NCL-L-CD20-L26, 1:200)",0.9,Accept,Experimental Usage
,CD8α,Unknown,Unknown,,,,,CD8α,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,CD8α (PA5-81344),0.85,Accept,Experimental Usage
,iNOS,Unknown,Unknown,,,,,iNOS,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"iNOS (ab15323, Abcam)",0.9,Accept,Experimental Usage
,mannose receptor,Unknown,Unknown,,,,,mannose receptor,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"mannose receptor (ab64693, Abcam)",0.9,Accept,Experimental Usage
,p-H3,Unknown,Unknown,,,,,p-H3,PMID:38502231 | PMID:39415595,10.1172/JCI176748 | 10.1242/dmm.050862,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,"p-H3 (ser10) (9701s, Cell Signaling Technology) | The embryos were incubated in anti-pH3 antibody overnight at 4°C",0.9,Accept,Experimental Usage
,cleaved PARP,Unknown,Unknown,,,,,cleaved PARP,PMID:38502231 | PMID:38714355 | PMID:33658640,10.1172/JCI176748 | 10.1158/1535-7163.MCT-23-0510 | 10.1038/s41416-021-01270-8,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"cleaved PARP (9488S, Cell Signaling Technology) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10)",0.9,Accept,Experimental Usage
,PD-1,Unknown,Unknown,,,,,PD-1,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,"anti–PD-1 (ab214421, Abcam; 66220-1-Ig, Proteintech) antibodies | 250 μg mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)",0.9,Accept,Experimental Usage
,IL6 receptor,Unknown,Monoclonal,,,Mouse,,IL6 receptor,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.,0.95,Accept,Experimental Usage
,TNFα,Unknown,Unknown,,,Mouse,,TNFα,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,Anti-mTNFα antibody (R023) was purchased from Sino Biological,0.95,Accept,Experimental Usage
,IL3,Unknown,Monoclonal,,,Mouse,,IL3,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,anti-mIL3 antibody (MP2–8F8) was purchased from BD Biosciences.,0.95,Accept,Experimental Usage
,βIII-tubulin,Mouse,Monoclonal,,,,,βIII-tubulin,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,The mouse anti-βIII-tubulin antibody Tuj1 was obtained from R&D system,0.95,Accept,Experimental Usage
,NGFR,Mouse,Monoclonal,,,,,NGFR,PMID:41022755 | PMID:38744290,10.1038/s41467-025-63619-4 | 10.1016/j.crmeth.2024.100772,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System | NGFR Biocare Medical CAT#ACI369A,0.95,Accept,Experimental Usage
,Human Nuclear Antigen,Rabbit,Recombinant,,,,,Human Nuclear Antigen,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher,0.95,Accept,Experimental Usage
,Drosophila neurofibromin,Mouse,Monoclonal,,,Drosophila,,Drosophila neurofibromin,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐ Drosophila neurofibromin (mouse, ascites purified mAb21 and mAb30, 1 : 500 each)",0.9,Accept,Experimental Usage
,human neurofibromin,Rabbit,,,,Human,,human neurofibromin,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"anti‐human neurofibromin (rabbit, Infixion r07E, San Diego, CA USA, 1 : 1000)",0.9,Accept,Experimental Usage
,phospho-ERK,Mouse,,,,Human,,phospho-ERK,PMID:39129390 | PMID:29847659 | PMID:34257279 | PMID:34011935 | PMID:38714355 | PMID:39472976 | PMID:18413802,10.1002/1878-0261.13704 | 10.1167/iovs.17-22588 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-07-0518,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"anti‐phospho‐ERK (mouse, Sigma M8159, 1 : 2500) | anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA) | Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10), anti-phospho-ERK (mouse, Sigma M8159, 1:2500) | phospho-ERK (#D13.14.4E) | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology | podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250) | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.9,Accept,Experimental Usage
,PARP,Rabbit,,,,,,PARP,PMID:39129390 | PMID:33658640 | PMID:25043298,10.1002/1878-0261.13704 | 10.1038/s41416-021-01270-8 | 10.1038/onc.2014.185,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Oncogenic role of Merlin/NF2 in glioblastoma.,,"anti‐PARP (rabbit, Cell Signaling 952, 1 : 1000) | total PARP (rabbit, #9542) (Cell Signaling, Danvers, MA, USA) | Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.9,Accept,Experimental Usage
,LC3B,Rabbit,,,,,,LC3B,PMID:39129390 | PMID:38203448,10.1002/1878-0261.13704 | 10.3390/ijms25010277,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti‐LC3B (rabbit, Cell Signaling 2775, 1 : 1000; CST Danvers, MA USA) | anti-LC3B (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage
,p44/42 MAPK (ERK1/2),Rabbit,Unknown,,,,,p44/42 MAPK (ERK1/2),PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage
,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),Rabbit,Unknown,,,,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage
,phosphatidylinositol 3-kinase (PI3K),Rabbit,Unknown,,,,,phosphatidylinositol 3-kinase (PI3K),PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs",0.95,Accept,Experimental Usage
,ATRX,Rabbit,Polyclonal,,,,,ATRX,PMID:31462295 | PMID:30531922 | PMID:35945463,10.1186/s40478-019-0792-5 | 10.1038/s41591-018-0263-8 | 10.1007/s00401-022-02478-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors. | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"using an ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich) | Primary ATRX antibody was from Sigma-Aldrich (HPA001906) and was used at 1:200 dilution | ATRX (Sigma, polyclonal, 1:100 dilution)",0.95,Accept,Experimental Usage
,GZMB,Unknown,Unknown,,,Human,,GZMB,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,"GZMB (Leica, PA0291, ready to use)",0.9,Accept,Experimental Usage
,CD68,Unknown,Unknown,,,Human,,CD68,PMID:30531922 | PMID:38216587,10.1038/s41591-018-0263-8 | 10.1038/s41467-023-40408-5,The molecular landscape of glioma in patients with Neurofibromatosis 1. | Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"CD68 (Sigma, HPA048982, 1:2,000) | or CD68 (M0814, Agilent Technologies; labeling validated using human B-cell lymphoma) primary antibodies",0.9,Accept,Experimental Usage
,"indoleamine 2,3-dioxygenase",Rabbit,Monoclonal,,,,,"indoleamine 2,3-dioxygenase",PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)",0.95,Accept,Experimental Usage
,AHR,Mouse,Monoclonal,,,,,AHR,PMID:38931352 | PMID:34011935,10.3390/ph17060685 | 10.1038/s41419-021-03802-9,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA) | Antibody for Aryl hydrocarbon receptor (AHR, #H-211)",0.95,Accept,Experimental Usage
,TDO2,Rabbit,Polyclonal,,,,,TDO2,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",0.95,Accept,Experimental Usage
,phospho-Merlin,Unknown,Unknown,,,,,phospho-Merlin,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage
,HDAC1,Unknown,Unknown,,,,,HDAC1,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage
,PDLIM2,Unknown,Unknown,,,,,PDLIM2,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology | PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore",0.9,Accept,Experimental Usage
,EMA,Unknown,Unknown,,,,,EMA,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.85,Accept,Experimental Usage
,vimentin,Mouse,Monoclonal,,,,,vimentin,PMID:30055648 | PMID:33356508 | PMID:39996452,10.1186/s13104-018-3630-0 | 10.1177/0963689720964383 | 10.1111/cns.70287,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. | Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4) | Vimentin-antigen presenting cell (APC) (expressed by C6 cells) | examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam.",0.9,Accept,Experimental Usage
,CD31,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,CD31,PMID:33442015 | PMID:29847659 | PMID:41444363 | PMID:34010628 | PMID:18483311 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1167/iovs.17-22588 | 10.1038/s41598-025-32031-9 | 10.1016/j.stem.2021.04.029 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam) | anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA) | Anti-CD31 (Abcam, ab7388) for vasculature | endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410) | Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature | CD31 (3528S, 1:100, Cell Signaling)",0.95,Accept,Experimental Usage
,AXL,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,AXL,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam) | pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",0.95,Accept,Experimental Usage
,pAXL,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,pAXL,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)",0.95,Accept,Experimental Usage
,pGSK-3β,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,pGSK-3β,PMID:33442015 | PMID:26904939,10.1038/s41591-020-01193-6 | 10.1016/j.celrep.2016.01.074,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.95,Accept,Experimental Usage
,pMEK1/2,Unknown,Unknown,,,"Human, Mouse",Non-conjugated,pMEK1/2,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)",0.95,Accept,Experimental Usage
,CalbindinD-28K,Rabbit,Polyclonal,,,,,CalbindinD-28K,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland | mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955), Munich, Germany",0.9,Accept,Experimental Usage
,MBP,Mouse,Monoclonal,,,,,MBP,PMID:29715273 | PMID:24509877 | PMID:40684195,10.1371/journal.pone.0196726 | 10.1038/onc.2013.506 | 10.1186/s40478-025-02075-z,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany) | Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | rat anti-MBP (1:200; Chemicon Millipore #MAB386)",0.9,Accept,Experimental Usage
,phospho-Histone H3,,,,,,,phospho-Histone H3,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)",0.9,Accept,Experimental Usage
,NF2,,Monoclonal,,,,,NF2,PMID:29715273 | PMID:26219339,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"anti-NF2 clone C-18, 1:500, Santa Cruz, Heidelberg, Germany | the NF2 polyclonal C26 antibody has been described",0.9,Accept,Experimental Usage
,phospho S518-Merlin,,,,,,,phospho S518-Merlin,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",0.9,Accept,Experimental Usage
,cyclophilin B,,,,,,,cyclophilin B,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK",0.9,Accept,Experimental Usage
,MAF,Unknown,Unknown,,,,,MAF,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage
,DEPTOR,Unknown,Unknown,,,,,DEPTOR,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)",0.9,Accept,Experimental Usage
,S100β,Unknown,Unknown,,,,,S100β,PMID:24509877 | PMID:21551250 | PMID:34040258 | PMID:40025578 | PMID:26904939 | PMID:40684195 | PMID:20049725,10.1038/onc.2013.506 | 10.1158/0008-5472.CAN-10-4577 | 10.1038/s41586-021-03580-6 | 10.1186/s40478-025-01965-6 | 10.1016/j.celrep.2016.01.074 | 10.1186/s40478-025-02075-z | 10.1002/emmm.200900027,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | S100β (rabbit, 1:5000, DAKO) | rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1) | S100β- Alexa Fluor 647 (Abcam, ab196175) | incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA | mouse anti-S100β (1:300; Abcam #ab218516) | We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody",0.9,Accept,Experimental Usage
,BLBP,Unknown,Unknown,,,,,BLBP,PMID:24509877 | PMID:25535838,10.1038/onc.2013.506 | 10.7554/eLife.05151,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore) | BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony)",0.9,Accept,Experimental Usage
,CD34,Mouse,Monoclonal,,,Human,FITC,CD34,PMID:29941005 | PMID:30055648 | PMID:38744290 | PMID:33767727,10.1186/s13023-018-0843-1 | 10.1186/s13104-018-3630-0 | 10.1016/j.crmeth.2024.100772 | 10.3389/fgene.2021.603195,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems)... | anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10) to demonstrate vessel and stem cell formation | CD34 Santa Cruz Biotechnology CAT#SC-74499; RRID: AB_1120394 | FITC Anti-CD34 antibody [4H11[APG]] (ab18227) | strong and diffuse CD34 positivity in the tumor cell cytoplasm",0.9,Accept,Experimental Usage
,RHAMM,Unknown,Unknown,,,,,RHAMM,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,Antibodies were sourced as follows: RHAMM (Epitomics),0.85,Accept,Experimental Usage
,TPX2,Unknown,Unknown,,,,,TPX2,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,TPX2 (Novus),0.85,Accept,Experimental Usage
,nestin,Unknown,Unknown,,,,,nestin,PMID:18451155 | PMID:36322658 | PMID:40684195 | PMID:23328114 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1126/sciadv.abo5442 | 10.1186/s40478-025-02075-z | 10.18632/oncotarget.793 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling) | Nestin (mouse; Millipore, MAB353), EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113) | rabbit anti-nestin (1:100; Abcam # ab221660) | nestin (Covance) | Anti-Nestin antibody primary IF CST (Danvers, USA)",0.95,Accept,Experimental Usage
,AURKA,Unknown,Unknown,,,,,AURKA,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)",0.85,Accept,Experimental Usage
,phospho-AURKA (Thr288),Unknown,Unknown,,,,,phospho-AURKA (Thr288),PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,phospho (p)-AURKA (Thr288),0.85,Accept,Experimental Usage
,p-histone H3 (Ser10),Unknown,Unknown,,,,,p-histone H3 (Ser10),PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,p-histone H3 (Ser10),0.85,Accept,Experimental Usage
,p-RHAMM (Thr703),Unknown,Polyclonal,,,,,p-RHAMM (Thr703),PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,The p-RHAMM (Thr703) polyclonal antibody is characterized in [11],0.9,Accept,Experimental Usage
,PDGFRβ,Rabbit,Unknown,,,,,PDGFRβ,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"we used antibodies to PDGFRβ (rabbit; Abcam, ab32570), α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547)",0.9,Accept,Experimental Usage
,α-SMA,Mouse,Monoclonal,,,,,α-SMA,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547), IBA1 (rabbit; Wako Chemicals, 019-19741)",0.9,Accept,Experimental Usage
,GLUT1,Rabbit,Unknown,,,,,GLUT1,PMID:36322658 | PMID:33934112 | PMID:38203448,10.1126/sciadv.abo5442 | 10.1038/s41419-021-03716-6 | 10.3390/ijms25010277,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"GLUT1 (rabbit; Abcam, ab652), cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661) | rabbit polyclonal anti-glucose transporter GLUT1 was from Abcam (Cat. #ab652) | anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies",0.9,Accept,Experimental Usage
,VEGFA,Rabbit,Unknown,,,,,VEGFA,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"VEGFA (rabbit; ABclonal, A0280), ALDH1A1 (rabbit; Proteintech, 15910-1-AP)",0.9,Accept,Experimental Usage
,ALDH1A1,Rabbit,Unknown,,,,,ALDH1A1,PMID:36322658 | PMID:36148553,10.1126/sciadv.abo5442 | 10.1093/brain/awac342,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,"ALDH1A1 (rabbit; Proteintech, 15910-1-AP), ZEB1 (rabbit; ABclonal, A5600) | ALDH1A1 (1:200; ab52492; Abcam)",0.9,Accept,Experimental Usage
,ZEB1,Rabbit,Unknown,,,,,ZEB1,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"ZEB1 (rabbit; ABclonal, A5600), IGFBP2 (rabbit; Cell Signaling Technology, #3922)",0.9,Accept,Experimental Usage
,IGFBP2,Rabbit,Unknown,,,,,IGFBP2,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"IGFBP2 (rabbit; Cell Signaling Technology, #3922), Nestin (mouse; Millipore, MAB353)",0.9,Accept,Experimental Usage
,EYA4,Rabbit,Unknown,,,,,EYA4,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113), SOX2 (goat; Santa Cruz Biotechnology, sc-17320)",0.9,Accept,Experimental Usage
,SOX2,,,,,,,SOX2,PMID:36730269 | PMID:36322658 | PMID:38744290 | PMID:36241865 | PMID:24371224,10.1371/journal.pone.0277305 | 10.1126/sciadv.abo5442 | 10.1016/j.crmeth.2024.100772 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-13-2062,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"SOX2 (Catalogue # MAB2018) from R&D systems | SOX2 (goat; Santa Cruz Biotechnology, sc-17320), and YAP/TAZ (rabbit; Cell Signaling Technology, #8418) | SOX2 Biocare Medical CAT#ACI3109A | Anti-SOX2 antibody primary IF CST | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.95,Accept,Experimental Usage
,YAP/TAZ,Rabbit,Unknown,,,,,YAP/TAZ,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,"YAP/TAZ (rabbit; Cell Signaling Technology, #8418). Secondary antibodies conjugated to Alexa Fluor 488",0.9,Accept,Experimental Usage
,GAP43,Rabbit,Unknown,,,,,GAP43,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,"GAP43 (rabbit, 1:1000, Abcam)",0.9,Accept,Experimental Usage
,p75 NGFR,Unknown,Unknown,,,,,p75 NGFR,PMID:37520682 | PMID:28256556,10.1016/j.omtn.2023.06.018 | 10.1038/srep43315,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,"Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection | anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)",0.9,Accept,Experimental Usage
,PDGFRα,Unknown,Polyclonal,,,,,PDGFRα,PMID:34040258 | PMID:40684195,10.1038/s41586-021-03580-6 | 10.1186/s40478-025-02075-z,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897) | goat anti-PDGFRα (1:100; R&D system #AF1062)",0.9,Accept,Experimental Usage
,NLGN3,Rabbit,Unknown,,,,,NLGN3,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108",0.9,Accept,Experimental Usage
,ADAM10,Rabbit,Unknown,,,,,ADAM10,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5",0.9,Accept,Experimental Usage
,caspase-3,Rabbit,Unknown,,,,,caspase-3,PMID:34040258 | PMID:30274821 | PMID:35511749 | PMID:38216572 | PMID:18367665,10.1038/s41586-021-03580-6 | 10.1016/j.ebiom.2018.09.042 | 10.1158/1535-7163.MCT-21-0947 | 10.1038/s41467-024-44755-9 | 10.1124/jpet.107.135830,NF1 mutation drives neuronal activity-dependent initiation of optic glioma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19 | caspase-3 (# 9662, Cell Signaling) | Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology | Caspase-3 (Cell Signaling Technologies, #9662, 1:1000 dilution) | Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)",0.9,Accept,Experimental Usage
,tau 1,,,,,,,tau 1,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)",0.85,Accept,Experimental Usage
,B-Actin,Unknown,Unknown,,,,,B-Actin,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)",0.9,Accept,Experimental Usage
,PTCH1,Unknown,Unknown,,,,,PTCH1,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,"PTCH1(1:500,Cat#MAB41051, R&D systems)",0.9,Accept,Experimental Usage
,β-catenin,Unknown,Unknown,,,,,β-catenin,PMID:23535903 | PMID:26904939,10.1158/2159-8290.CD-13-0081 | 10.1016/j.celrep.2016.01.074,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.",,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (β-catenin, 1:100, Cell Signaling) | The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling) | Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200) | anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage
,activated β-catenin,Unknown,Unknown,,,,,activated β-catenin,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage
,GSK3B,Unknown,Unknown,,,,,GSK3B,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage
,AXIN1,Unknown,Unknown,,,,,AXIN1,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)",0.9,Accept,Experimental Usage
,CCND1,Unknown,Monoclonal,,,,,CCND1,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)",0.9,Accept,Experimental Usage
,HK2,Unknown,Polyclonal,,,,,HK2,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"primary goat polyclonal anti‐HK2 (sc‐6521, Santa Cruz) and rabbit monoclonal anti‐MPP2 | Primary antibodies (rabbit monoclonal anti‐HK2, H.738.7, Thermo Scientific; mouse monoclonal anti‐TOM20",0.95,Accept,Experimental Usage
,MPP2,Rabbit,Monoclonal,,,,,MPP2,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"rabbit monoclonal anti‐MPP2 (ab92536, Abcam) antibodies",0.95,Accept,Experimental Usage
,ATP5A,Unknown,Unknown,,,,,ATP5A,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"ATP5A (ab14748, Abcam), anti‐UQCRC2 (ab14745, Abcam)",0.95,Accept,Experimental Usage
,UQCRC2,Unknown,Unknown,,,,,UQCRC2,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"anti‐UQCRC2 (ab14745, Abcam), rabbit monoclonal anti‐MMP2 (ab92536, Abcam)",0.95,Accept,Experimental Usage
,MMP9,Rabbit,Monoclonal,,,,,MMP9,PMID:32383545 | PMID:23175151,10.15252/embr.201949117 | 10.1038/bjc.2012.518,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"rabbit monoclonal anti‐MMP9 (ab137867, Abcam) rabbit polyclonal, and TOM20 | rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam",0.95,Accept,Experimental Usage
,TOM20,Unknown,Unknown,,,,,TOM20,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,"TOM20 (sc‐11415, Santa Cruz) antibodies | mouse monoclonal anti‐TOM20, sc‐17764, Santa Cruz) were diluted 1:150",0.95,Accept,Experimental Usage
,Beta-Actin,,,,,,,Beta-Actin,PMID:36730269 | PMID:41564118 | PMID:38481529,10.1371/journal.pone.0277305 | 10.1371/journal.pone.0340183 | 10.3389/fcell.2024.1359561,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,"Beta-Actin (Catalogue # NB600-501) was purchased from Novus | beta-actin (Cell Signaling cat# 3700 1:10000) | Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading",0.95,Accept,Experimental Usage
,neurofibromin/NF1,Unknown,Unknown,,,,,neurofibromin/NF1,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)",0.95,Accept,Experimental Usage
,FBXW11/bTrCP2,Unknown,Unknown,,,,,FBXW11/bTrCP2,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)",0.95,Accept,Experimental Usage
,pERK Thr202/Tyr204,Unknown,Unknown,,,,,pERK Thr202/Tyr204,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)",0.95,Accept,Experimental Usage
,TRAP1,Mouse,Monoclonal,,,Human,,TRAP1,PMID:35614131 | PMID:33934112,10.1038/s41418-022-01020-0 | 10.1038/s41419-021-03716-6,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,mouse monoclonal anti-human TRAP1 (sc-73604) | Mouse monoclonal anti-rodent TRAP1 was from Becton Dickinson (Cat. #612344) | mouse monoclonal anti-human TRAP1 was from Santa Cruz (Cat. #sc-73604),0.9,Accept,Experimental Usage
,ATP50/OSCP,Mouse,Monoclonal,,,,,ATP50/OSCP,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti ATP50/OSCP (ab110276) antibodies,0.9,Accept,Experimental Usage
,ATPB,Mouse,Monoclonal,,,,,ATPB,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti-ATPB (ab14730),0.9,Accept,Experimental Usage
,SDHA,Mouse,Monoclonal,,,,,SDHA,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,anti SDHA (sc-166947),0.9,Accept,Experimental Usage
,Cyclophilin,Mouse,Monoclonal,,,,,Cyclophilin,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,mouse monoclonal anti-Cyclophilin (ab110324) antibodies,0.9,Accept,Experimental Usage
,synaptophysin,Unknown,Polyclonal,,,,,synaptophysin,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"synaptophysin (Cell Marque, polyclonal, 1:100 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage
,p16,Unknown,Monoclonal,,,,,p16,PMID:35945463 | PMID:34065204 | PMID:30055648,10.1007/s00401-022-02478-5 | 10.3390/ijms22105367 | 10.1186/s13104-018-3630-0,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,"p16 (MTM Labs, clone E6H4, undiluted, ER1 antigen retrieval) | human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam | mouse p16 (sc-1207, 1:200) from Santa Cruz Biotechnology | anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9",0.9,Accept,Experimental Usage
,histone H3 K27M mutant protein,Unknown,Monoclonal,,,,,histone H3 K27M mutant protein,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"histone H3 K27M mutant protein (RevMAb Biosciences, clone RM192, 1:600 dilution)",0.9,Accept,Experimental Usage
,histone H3 lysine 27 trimethylation,Unknown,Monoclonal,,,,,histone H3 lysine 27 trimethylation,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,"histone H3 lysine 27 trimethylation (Cell Signaling, cat #9733, clone C36B11, 1:50 dilution, ER2 antigen retrieval)",0.9,Accept,Experimental Usage
,CD16/CD32,Unknown,Unknown,,,,,CD16/CD32,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min,0.9,Accept,Experimental Usage
,MMP2,Mouse,Monoclonal,,,,,MMP2,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam",0.95,Accept,Experimental Usage
,MMP3,,,,,,,MMP3,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc.)",0.85,Accept,Experimental Usage
,CD24,Unknown,Monoclonal,,,Human,APC,CD24,PMID:40217315 | PMID:24371224,10.1186/s13073-025-01462-4 | 10.1158/0008-5472.CAN-13-2062,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec) | 1 × 106 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences)",0.95,Accept,Experimental Usage
,CD44,Unknown,Monoclonal,,,Human,VioBlue,CD44,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec) and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)",0.95,Accept,Experimental Usage
,HLA Class I ABC,Unknown,Unknown,,,Human,Non-conjugated,HLA Class I ABC,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I",0.95,Accept,Experimental Usage
,MHC Class II,Unknown,Unknown,,,Human,Non-conjugated,MHC Class II,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,"DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II",0.95,Accept,Experimental Usage
,Pericentrin,,,,,Human,Non-conjugated,Pericentrin,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",0.9,Accept,Experimental Usage
,γTubulin,,,,,Human,Non-conjugated,γTubulin,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes",0.9,Accept,Experimental Usage
,Acetylated Tubulin,,,,,Human,Non-conjugated,Acetylated Tubulin,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"and Acetylated Tubulin to mark cilia (T6793, Sigma; labeling validated in vertebrate and invertebrate organisms)",0.9,Accept,Experimental Usage
,CD13,Mouse,Monoclonal,,,Human,FITC,CD13,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...incubated for 30 min in ice and in the dark with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)...",0.9,Accept,Experimental Usage
,CD14,Mouse,Monoclonal,,,Human,PE,CD14,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK), CD14/PE (M5E2, BD Biosciences, CA, USA)...",0.9,Accept,Experimental Usage
,CD105,Mouse,Monoclonal,,,Human,APC,CD105,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences)...",0.9,Accept,Experimental Usage
,CD146,Mouse,Monoclonal,,,Human,PE,CD146,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences)...",0.9,Accept,Experimental Usage
,CD271,Mouse,Monoclonal,,,Human,APC,CD271,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls...",0.9,Accept,Experimental Usage
,OCT3/4,Unknown,Unknown,,,Human,,OCT3/4,PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.9,Accept,Experimental Usage
,NANOG,Unknown,Unknown,,,Human,,NANOG,PMID:37990867 | PMID:24371224,10.1242/dmm.049861 | 10.1158/0008-5472.CAN-13-2062,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4) | Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin",0.9,Accept,Experimental Usage
,TRA-1-60,Unknown,Unknown,,,Human,,TRA-1-60,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage
,SSEA-4,Unknown,Unknown,,,Human,,SSEA-4,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)",0.9,Accept,Experimental Usage
,MKK3,Unknown,Unknown,,,,,MKK3,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674),0.9,Accept,Experimental Usage
,p38,Unknown,Unknown,,,,,p38,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,p38 (Cell Signaling #9219),0.9,Accept,Experimental Usage
,phospho-p38,Unknown,Unknown,,,,,phospho-p38,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,phospho-p38 (Cell Signaling # 4511),0.9,Accept,Experimental Usage
,TAZ,Rabbit,Unknown,,,,,TAZ,PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,"we used antibodies to TAZ (Rabbit; Proteintech 23306-1), YAP (Rabbit; Cell Signaling Technology, #4912) | TAZ (1:100; sc-48805; Santa Cruz)",0.9,Accept,Experimental Usage
,YAP,Rabbit,Unknown,,,,,YAP,PMID:29438698 | PMID:36148553,10.1016/j.ccell.2018.01.005 | 10.1093/brain/awac342,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,"YAP (Rabbit; Cell Signaling Technology, #4912), TAZ/YAP (Rabbit; Cell Signaling Technology, #8418) | YAP (1:100; #14074; CST)",0.9,Accept,Experimental Usage
,TAZ/YAP,Rabbit,Unknown,,,,,TAZ/YAP,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"TAZ/YAP (Rabbit; Cell Signaling Technology, #8418), Sox10 (Goat, Santa Cruz Biotechnology, sc-17342",0.9,Accept,Experimental Usage
,TEAD1,Mouse,Unknown,,,,,TEAD1,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,"TEAD1 (Mouse, Santa Cruz Biotechnology sc-393976), neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67) | The antibodies used were as follows: TEAD1 (Mouse, BD Biosciences, 610922), H3K4me1 (Rabbit, Abcam, 8895)",0.9,Accept,Experimental Usage
,phospho-Akt,Unknown,Unknown,,,,Non-conjugated,phospho-Akt,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage
,Ubiquitin,,,,,,,Ubiquitin,PMID:36730269 | PMID:36689660,10.1371/journal.pone.0277305 | 10.1073/pnas.2208960120,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"Ubiquitin (Catalogue # 4289) | HA, HSP70, and Ubiquitin (Cell Signaling)",0.95,Accept,Experimental Usage
,pCHEK1 S296,,,,,,,pCHEK1 S296,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pCHEK1 S296 (Catalogue # 90178),0.95,Accept,Experimental Usage
,BMI1,,,,,,,BMI1,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,BMI1 (Catalogue # 5856),0.95,Accept,Experimental Usage
,H3K27Ac,,,,,,,H3K27Ac,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,H3K27Ac (Catalogue # 8173),0.95,Accept,Experimental Usage
,H3,,,,,,,H3,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,total H3 (Catalogue # 14269),0.95,Accept,Experimental Usage
,CDK9,,,,,,,CDK9,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CDK9 (Catalogue # 2316),0.95,Accept,Experimental Usage
,CPNase,,,,,,,CPNase,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,CPNase (Catalogue # 5664),0.95,Accept,Experimental Usage
,MAG,,,,,,,MAG,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,MAG (Catalogue # 9043),0.95,Accept,Experimental Usage
,pS2 RNApol II,,,,,,,pS2 RNApol II,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore,0.95,Accept,Experimental Usage
,EGFR,Unknown,Monoclonal,,,,,EGFR,PMID:20195187 | PMID:28166733 | PMID:25043298,10.1097/MAO.0b013e3181d2777f | 10.1186/s12864-017-3519-7 | 10.1038/onc.2014.185,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | Oncogenic role of Merlin/NF2 in glioblastoma.,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA) | anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT) | Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",0.9,Accept,Experimental Usage
,ErbB2,Unknown,Polyclonal,,,,,ErbB2,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",0.9,Accept,Experimental Usage
,actin,Unknown,Monoclonal,,,,,actin,PMID:20195187 | PMID:30055648 | PMID:36420221 | PMID:33658640,10.1097/MAO.0b013e3181d2777f | 10.1186/s13104-018-3630-0 | 10.1016/j.omtn.2022.10.026 | 10.1038/s41416-021-01270-8,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"monoclonal anti-actin (BD Biosciences, San Jose, CA) | anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4). Staining was visualized using the ultraView™ Universal Alkaline Phosphatase Red Detection Kit | An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes) | Actin (mouse, ACTN05(C4), NeoMarkers) at 1:1000 dilution",0.9,Accept,Experimental Usage
,MPM-2,Unknown,Unknown,,,,,MPM-2,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY)",0.85,Accept,Experimental Usage
,cyclin D1,Rabbit,Monoclonal,,,Human,,cyclin D1,PMID:32948135 | PMID:30274821 | PMID:33032988 | PMID:18413802,10.1186/s12885-020-07397-w | 10.1016/j.ebiom.2018.09.042 | 10.1158/0008-5472.CAN-20-1365 | 10.1158/1535-7163.MCT-07-0518,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO) | cyclinD1 (# C7464, Sigma-Aldrich) | Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology | Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.95,Accept,Experimental Usage
,B-Raf,Unknown,Unknown,,,,,B-Raf,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)",0.85,Accept,Experimental Usage
,phospho-MEK1/2,Unknown,Monoclonal,,,,,phospho-MEK1/2,PMID:34011935 | PMID:18413802,10.1038/s41419-021-03802-9 | 10.1158/1535-7163.MCT-07-0518,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"phospho-MEK1/2 (#41G9) | phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",0.9,Accept,Experimental Usage
,phospho-Rb,Unknown,Unknown,,,,,phospho-Rb,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)",0.85,Accept,Experimental Usage
,MDM2,Unknown,Unknown,,,,,MDM2,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich)",0.9,Accept,Experimental Usage
,CXCL12,Unknown,Polyclonal,,,,,CXCL12,PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12 | purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12) | Antibodies were obtained from Peprotech (CXCL12),0.9,Accept,Experimental Usage
,Endoglin,Unknown,Polyclonal,,,,,Endoglin,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,R&D (Goat anti-Endoglin),0.9,Accept,Experimental Usage
,p-PKA substrate,Unknown,Unknown,,,,,p-PKA substrate,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.9,Accept,Experimental Usage
,pS473-AKT,Unknown,Unknown,,,,,pS473-AKT,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)",0.9,Accept,Experimental Usage
,CXCR4,Unknown,Unknown,,,,,CXCR4,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,Leinco (pan-CXCR4),0.9,Accept,Experimental Usage
,CNPase,Unknown,Unknown,,,,,CNPase,PMID:18451155 | PMID:20554030 | PMID:23685747 | PMID:36241865 | PMID:20551058,10.1158/0008-5472.CAN-07-6867 | 10.1016/j.jneuroim.2010.05.002 | 10.1038/ng.2641 | 10.1038/s12276-022-00850-9 | 10.1158/0008-5472.CAN-09-3769,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,"Gfap (Dako), CNPase (Chemicon), or nestin | Sigma (mouse anti-CNPase) | Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz) | Anti-CNPase antibody primary IF and WB CST | Sigma (CNPase)",0.95,Accept,Experimental Usage
,phosphorylated CXCR4,Unknown,Unknown,,,,,phosphorylated CXCR4,PMID:20554030 | PMID:20551058,10.1016/j.jneuroim.2010.05.002 | 10.1158/0008-5472.CAN-09-3769,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab | Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described,0.9,Accept,Experimental Usage
,phosphorylated PKA,Unknown,Unknown,,,,,phosphorylated PKA,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage
,PKA,Unknown,Unknown,,,,,PKA,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage
,phosphorylated CREB,Unknown,Unknown,,,,,phosphorylated CREB,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage
,CREB,Unknown,Unknown,,,,,CREB,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology,0.95,Accept,Experimental Usage
,P-glycoprotein,Unknown,Unknown,,,Human,Non-conjugated,P-glycoprotein,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch",0.9,Accept,Experimental Usage
,p-4EBP,Unknown,Unknown,,,,,p-4EBP,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,p-4EBP (Cell Signaling 1:500),0.9,Accept,Experimental Usage
,HSP70,Unknown,Unknown,,,,,HSP70,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,"HA, HSP70, and Ubiquitin (Cell Signaling)",0.85,Accept,Experimental Usage
,GST,Unknown,Unknown,,,,,GST,PMID:21072183 | PMID:36689660,10.1371/journal.pone.0013791 | 10.1073/pnas.2208960120,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,The antibodies used in this study include... GST (Santa Cruz Biotechnology) | GST and Vinculin (Bethyl Laboratories),0.9,Accept,Experimental Usage
,RASA1,Unknown,Unknown,,,,,RASA1,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,RASA1 (Santa Cruz Biotechnology),0.85,Accept,Experimental Usage
,p-RB1-S807/811,Unknown,Unknown,,,,Non-conjugated,p-RB1-S807/811,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",0.95,Accept,Experimental Usage
,RB1,Unknown,Unknown,,,,Non-conjugated,RB1,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology",0.9,Accept,Experimental Usage
,RABL6A,Unknown,Monoclonal,,,,Non-conjugated,RABL6A,PMID:34065204 | PMID:37410426,10.3390/ijms22105367 | 10.1158/1078-0432.CCR-23-0749,"RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,RABL6A antibodies (monoclonal and polyclonal) were produced in the Quelle laboratory | Immunostaining for SIAH (24E6H3 mouse monoclonal antibody) and RABL6A was conducted,0.9,Accept,Experimental Usage
,nc82,Mouse,Unknown,,,,,nc82,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,"The following antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), mouse anti-nc82 (1:50, DSHB)",0.9,Accept,Experimental Usage
,FOXR2,Unknown,Unknown,,,,,FOXR2,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,"Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed",0.9,Accept,Experimental Usage
,Nuclear Pore Complex Proteins,Unknown,Unknown,,,Human,,Nuclear Pore Complex Proteins,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)",0.9,Accept,Experimental Usage
,HER1,Rabbit,Unknown,,,Human,Non-conjugated,HER1,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER1 (Abcam, ab52894) | HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)",0.9,Accept,Experimental Usage
,HER2,Rabbit,Unknown,,,Human,Non-conjugated,HER2,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",0.9,Accept,Experimental Usage
,VEGFR2,Rabbit,Unknown,,,Human,Non-conjugated,VEGFR2,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human VEGFR2 (CST, 9698S)",0.9,Accept,Experimental Usage
,B7H3,Rabbit,Unknown,,,Human,Non-conjugated,B7H3,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human B7H3 (CST, #14058)",0.9,Accept,Experimental Usage
,CD171,Rabbit,Unknown,,,Human,Non-conjugated,CD171,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human CD171 (Abcam, ab208155)",0.9,Accept,Experimental Usage
,EGFRvIII,Rabbit,Unknown,,,Human,Non-conjugated,EGFRvIII,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",0.9,Accept,Experimental Usage
,TGFβ1,Rabbit,Unknown,,,Human,Non-conjugated,TGFβ1,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"rabbit anti-human TGFβ1 (Abcam, ab215715)",0.9,Accept,Experimental Usage
,CD8a,Unknown,Unknown,,,Human,APC,CD8a,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206)",0.85,Accept,Experimental Usage
,CD45RO,Unknown,Unknown,,,Human,PE,CD45RO,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242)",0.85,Accept,Experimental Usage
,CCR7,Unknown,Unknown,,,Human,PerCP,CCR7,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,"CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)",0.85,Accept,Experimental Usage
,Mek1/2,Unknown,Unknown,,,,,Mek1/2,PMID:21072183 | PMID:34011935,10.1371/journal.pone.0013791 | 10.1038/s41419-021-03802-9,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology) | Antibodies used in western blotting targeting...MEK1/2,0.9,Accept,Experimental Usage
,MMP1,Unknown,Monoclonal,,,,,MMP1,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,MMP1 (#E9S9N),0.9,Accept,Experimental Usage
,collagen I,Unknown,Monoclonal,,,,,collagen I,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,collagen I (#EPR7785),0.9,Accept,Experimental Usage
,S100 protein,Unknown,Unknown,,,,,S100 protein,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,anti-S100 protein antibody (Nichirei Biosciences Inc.),0.85,Accept,Experimental Usage
,neurofibromin 1,Rabbit,Monoclonal,,,,,neurofibromin 1,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Primary and secondary antibodies used were from Cell Signaling Technology: neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543),0.95,Accept,Experimental Usage
,Ki67 antigen,Unknown,Unknown,,,,,Ki67 antigen,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma)",0.95,Accept,Experimental Usage
,glial fibrillary acidic protein,Unknown,Unknown,,,,,glial fibrillary acidic protein,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)",0.95,Accept,Experimental Usage
,phosphorylated Akt,Unknown,Unknown,,,,,phosphorylated Akt,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)",0.95,Accept,Experimental Usage
,BrdUrd,Unknown,Unknown,,,,,BrdUrd,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)",0.95,Accept,Experimental Usage
,doublecortin,Unknown,Unknown,,,,,doublecortin,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval for all antibodies, except for doublecortin antibody",0.95,Accept,Experimental Usage
,β3-tubulin,Unknown,Unknown,,,,,β3-tubulin,PMID:18451155 | PMID:36241865,10.1158/0008-5472.CAN-07-6867 | 10.1038/s12276-022-00850-9,Pten haploinsufficiency accelerates formation of high-grade astrocytomas. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin | Anti-β3-Tubulin antibody primary IF and WB CST",0.95,Accept,Experimental Usage
,S100A10,,Polyclonal,,,,,S100A10,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems),0.85,Accept,Experimental Usage
,Cdk1,Rabbit,Monoclonal,,,,,Cdk1,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,phospho-Cdk1 Tyr15,Rabbit,Monoclonal,,,,,phospho-Cdk1 Tyr15,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,Histone H3,Rabbit,Monoclonal,,,,,Histone H3,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,Acetyl-Histone H3 Lys18,Rabbit,Monoclonal,,,,,Acetyl-Histone H3 Lys18,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,SAPK/JNK,Rabbit,Monoclonal,,,,,SAPK/JNK,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,phospho-SAPK/JNK Thr183/Tyr185,Rabbit,Monoclonal,,,,,phospho-SAPK/JNK Thr183/Tyr185,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,p70S6 Kinase,Rabbit,Monoclonal,,,,,p70S6 Kinase,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,phospho-p70 Thr389 S6 Kinase,Rabbit,Monoclonal,,,,,phospho-p70 Thr389 S6 Kinase,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology",0.9,Accept,Experimental Usage
,phospho-S6 (Ser240/244),,,,,,Alexa Fluor 488,phospho-S6 (Ser240/244),PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)",0.9,Accept,Experimental Usage
,phospho-S6 (S240/244),,,,,,,phospho-S6 (S240/244),PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)",0.9,Accept,Experimental Usage
,phospho-p70 S6K (T389),,,,,,,phospho-p70 S6K (T389),PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-p70 S6K (T389), p70 S6K, phospho-Akt (S473)",0.9,Accept,Experimental Usage
,phospho-Akt (S473),,,,,,,phospho-Akt (S473),PMID:26219339 | PMID:18483311,10.18632/oncotarget.4858 | 10.1158/1535-7163.MCT-07-2335,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346) | Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage
,phospho-NDRG1 (T346),,,,,,,phospho-NDRG1 (T346),PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-NDRG1 (T346), SGK1, phospho-PAK1 (S144)",0.9,Accept,Experimental Usage
,SGK1,,,,,,,SGK1,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"SGK1, phospho-PAK1 (S144), PAK1",0.9,Accept,Experimental Usage
,phospho-PAK1 (S144),,,,,,,phospho-PAK1 (S144),PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"phospho-PAK1 (S144), PAK1, and 4EBP1",0.9,Accept,Experimental Usage
,PAK1,,,,,,,PAK1,PMID:26219339 | PMID:21072183,10.18632/oncotarget.4858 | 10.1371/journal.pone.0013791,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,"PAK1, and 4EBP1 were from Cell Signaling Technology | The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology)",0.9,Accept,Experimental Usage
,4EBP1,,,,,,,4EBP1,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"PAK1, and 4EBP1 were from Cell Signaling Technology",0.9,Accept,Experimental Usage
,Rac1,,,,,,,Rac1,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rac1 (BD Biosciences; San Jose, CA)",0.9,Accept,Experimental Usage
,Rheb,,Monoclonal,,,,,Rheb,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)",0.9,Accept,Experimental Usage
,tubulin,Mouse,Monoclonal,,,,,tubulin,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)",0.9,Accept,Experimental Usage
,SUZ12,Rabbit,Monoclonal,,,,,SUZ12,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,"SUZ12 D39F6 #3737 (Cell Signaling, rabbit, 2% milk, 1:1000, overnight, 4 °C)",0.9,Accept,Experimental Usage
,Pak2,Unknown,Unknown,,,,,Pak2,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology),0.9,Accept,Experimental Usage
,phospho-MEK1 (Ser298),Unknown,Unknown,,,,,phospho-MEK1 (Ser298),PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-MEK1 (Ser298)... (Cell Signaling Technology),0.95,Accept,Experimental Usage
,phospho-Erk1/2 (Thr202/Tyr204),Unknown,Unknown,,,,,phospho-Erk1/2 (Thr202/Tyr204),PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Erk1/2 (Thr202/Tyr204)... (Cell Signaling Technology),0.95,Accept,Experimental Usage
,phospho-Akt (Thr308),Unknown,Unknown,,,,,phospho-Akt (Thr308),PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Akt (Thr308)... (Cell Signaling Technology),0.95,Accept,Experimental Usage
,phospho-Pak1–3 (Ser141),Unknown,Unknown,,,,,phospho-Pak1–3 (Ser141),PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,The antibodies used in this study include... phospho-Pak1–3 (Ser141; Invitrogen),0.95,Accept,Experimental Usage
,DUSP6,Unknown,Unknown,,,,,DUSP6,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,Antibodies against DUSP6 (# ab76310) were from Abcam,0.9,Accept,Experimental Usage
,panendothelial cell antigen,Unknown,Unknown,,,,,panendothelial cell antigen,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)",0.9,Accept,Experimental Usage
,P-Stat3 (Y705),,,,,,,P-Stat3 (Y705),PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)",0.9,Accept,Experimental Usage
,P-Jak2,,,,,,,P-Jak2,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage
,Jak2,,,,,,,Jak2,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage
,p-STAT3,Rabbit,Monoclonal,,,,,p-STAT3,PMID:33658640 | PMID:26904939,10.1038/s41416-021-01270-8 | 10.1016/j.celrep.2016.01.074,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"p-STAT3 (Y705) (rabbit monoclonal 1:25 dilution, Cell Signaling, D3A7) | Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.95,Accept,Experimental Usage
,Stat3,,,,,,,Stat3,PMID:26904939 | PMID:33658640,10.1016/j.celrep.2016.01.074 | 10.1038/s41416-021-01270-8,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA) | STAT3 (mouse, 124H6), Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10), total PARP (rabbit, #9542) (Cell Signaling",0.9,Accept,Experimental Usage
,P-β-catenin,,,,,,,P-β-catenin,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage
,GSK3β,,,,,,,GSK3β,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)",0.9,Accept,Experimental Usage
,CD16/32,Unknown,Unknown,,,Mouse,,CD16/32,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)",0.9,Accept,Experimental Usage
,Ter119,Unknown,Unknown,,,,PE,Ter119,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 116208)",0.9,Accept,Experimental Usage
,p75,Unknown,Unknown,,,,,p75,PMID:18242513 | PMID:38175707,10.1016/j.ccr.2008.01.003 | 10.1172/jci.insight.168826,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon) | incubated for 30 minutes on ice with unconjugated primary antibody p75 (1:1,000, Ab3125, Abcam)",0.95,Accept,Experimental Usage
,α4 integrin,Unknown,Unknown,,,,,α4 integrin,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)",0.9,Accept,Experimental Usage
,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",,,,,Mouse,Biotin,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs",0.9,Accept,Experimental Usage
,phospho-histone-H3 (Ser 10),Unknown,Unknown,,,,,phospho-histone-H3 (Ser 10),PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc.",0.85,Accept,Experimental Usage
,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",Unknown,Unknown,,,,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution",0.8,Accept,Experimental Usage
,phospho-MEK,Unknown,Unknown,,,,,phospho-MEK,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage
,RAD51,Unknown,Unknown,,,,,RAD51,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody | Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.95,Accept,Experimental Usage
,BRCA2,Unknown,Unknown,,,,,BRCA2,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology",0.9,Accept,Experimental Usage
,MGMT,Unknown,Unknown,,,,,MGMT,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,MGMT (sc-166528) was obtained from Santa Cruz Biotechnology,0.95,Accept,Experimental Usage
,yH2AX,Unknown,Unknown,,,,,yH2AX,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody",0.95,Accept,Experimental Usage
,Ago2,Unknown,Unknown,,,,,Ago2,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50",0.85,Accept,Experimental Usage
,citrate synthetase,Rabbit,Polyclonal,,,,,citrate synthetase,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,rabbit polyclonal anti-citrate synthetase was from Abcam (Cat. #ab96600),0.9,Accept,Experimental Usage
,Etv5,Rabbit,Unknown,,,,,Etv5,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry,0.9,Accept,Experimental Usage
,podoplanin,Unknown,Monoclonal,,,Human,Non-conjugated,podoplanin,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)",0.9,Accept,Experimental Usage
,F4/80,Rat,Unknown,,,,,F4/80,PMID:40684195 | PMID:28256556,10.1186/s40478-025-02075-z | 10.1038/srep43315,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,rat anti-F4/80 (1:400; Abcam #ab6640) | anti-F4/80 bound to Cy5.5 on ice in a solution containing phosphate-buffered saline,0.9,Accept,Experimental Usage
,CSF1,Unknown,Monoclonal,,,Mouse,Non-conjugated,CSF1,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium,0.9,Accept,Experimental Usage
,tomato,Rat,Unknown,,,,,tomato,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rat anti-tomato (1:1000; Kerafast #EST203),0.9,Accept,Experimental Usage
,cKIT,Goat,Unknown,,,,,cKIT,PMID:40684195 | PMID:38744290,10.1186/s40478-025-02075-z | 10.1016/j.crmeth.2024.100772,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,goat anti-cKIT (1:100; R&D system #AF1356) | APC Anti-c-Kit antibody [YB5.B8] (ab95678),0.9,Accept,Experimental Usage
,POSTN,Goat,Unknown,,,,,POSTN,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,goat anti-POSTN (1:400; BioTechne #AF2955),0.9,Accept,Experimental Usage
,TNC,Rabbit,Unknown,,,,,TNC,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-TNC (1:100; Abcam #ab108930),0.9,Accept,Experimental Usage
,PGP9.5,Rabbit,Unknown,,,,,PGP9.5,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,rabbit anti-PGP9.5 (1:100; Abcam #ab108986),0.9,Accept,Experimental Usage
,Aqp1,Mouse,Unknown,,,,Alexa Fluor 488,Aqp1,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,mouse A488-anti-Aqp1 (1:100; Santa Cruz Biotech #sc-25287),0.9,Accept,Experimental Usage
,KIF11,Unknown,Unknown,,,,,KIF11,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,incubated with anti-KIF11 antibody (Proteintech),0.9,Accept,Experimental Usage
,KIF15,Unknown,Unknown,,,,,KIF15,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,anti-KIF15 antibody (Proteintech),0.9,Accept,Experimental Usage
,PGDS,Rabbit,Polyclonal,,,,,PGDS,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)",0.9,Accept,Experimental Usage
,phospho-S6K (T389),Rabbit,Monoclonal,,,,,phospho-S6K (T389),PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology",0.9,Accept,Experimental Usage
,S6K1,Unknown,Unknown,,,,,S6K1,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,Total S6K1 antibody was used as previously described,0.9,Accept,Experimental Usage
,Mib1,Unknown,Unknown,,,,,Mib1,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)",0.9,Accept,Experimental Usage
,PDE4A,Unknown,Unknown,,,,,PDE4A,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Abcam (PDE4A & 58kD Golgi marker),0.8,Accept,Experimental Usage
,LCA,Unknown,Unknown,,,,,LCA,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Pharmingen (LCA),0.8,Accept,Experimental Usage
,phosphorylated protein kinase A substrate,Unknown,Unknown,,,,,phosphorylated protein kinase A substrate,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Cell Signaling (phosphorylated protein kinase A (pPKA) substrate),0.8,Accept,Experimental Usage
,Ly6G,Unknown,Unknown,,,Mouse,Non-conjugated,Ly6G,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,Depletion of neutrophils via anti-Ly6G antibody or bone marrow suppression using hydroxyurea significantly improved tumor clearance.,0.9,Accept,Experimental Usage
,MPZ,,Unknown,,,,,MPZ,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,"MPZ (1:100, Ab183868, Abcam), overnight at 4ºC",0.95,Accept,Experimental Usage
,Survivin,Unknown,Unknown,,,,,Survivin,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"Survivin (MA5–15077, 1:200, Invitrogen)",0.9,Accept,Experimental Usage
,CENPF,Unknown,Unknown,,,,,CENPF,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,"CENPF (PA5–84637, 1:200, Invitrogen) | CENPF (ab223847, 1:1000 dilution, Abcam)",0.9,Accept,Experimental Usage
,CD56,Mouse,Unknown,,,Unknown,Non-conjugated,CD56,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD56 Biocare Medical CAT#CM164A,0.9,Accept,Experimental Usage
,CD117/c-kit,Rabbit,Unknown,,,Unknown,Non-conjugated,CD117/c-kit,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,CD117/c-kit Biocare Medical CAT#CME296AK; RRID: AB_10581782,0.9,Accept,Experimental Usage
,PanCytokeratin,Mouse,Unknown,,,Unknown,Non-conjugated,PanCytokeratin,PMID:38744290 | PMID:24371224,10.1016/j.crmeth.2024.100772 | 10.1158/0008-5472.CAN-13-2062,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,PanCytokeratin Biocare Medical CAT#CM011A; RRID: AB_2811020 | Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma),0.9,Accept,Experimental Usage
,S100A11,Unknown,Recombinant,,,Unknown,PE,S100A11,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Recombinant PE Anti-S100A11 antibody [EPR11172] (ab211996),0.9,Accept,Experimental Usage
,beta tubulin,,,,,,,beta tubulin,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"beta tubulin (Developmental Hybridoma Studies Bank, #E7, 1:10,000 dilution)",0.9,Accept,Experimental Usage
,pMEK,,,,,,,pMEK,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pMEK (Cell Signaling Technologies, #9121, 1:1000 dilution)",0.9,Accept,Experimental Usage
,MEK,,,,,,,MEK,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"total MEK (Cell Signaling Technologies, #8727, 1:1000 dilution)",0.9,Accept,Experimental Usage
,pPAK,,,,,,,pPAK,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"pPAK (Cell Signaling Technologies, #2601, 1:1000 dilution)",0.9,Accept,Experimental Usage
,Caspase-7,,,,,,,Caspase-7,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,"Caspase-7 (Cell Signaling Technologies, #9492, 1:1,000 dilution)",0.9,Accept,Experimental Usage
,Neurofilament,Unknown,Unknown,,,,,Neurofilament,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Neurofilament (1:1000; ab4680; Abcam),0.9,Accept,Experimental Usage
,Pan-TEAD,Unknown,Unknown,,,,,Pan-TEAD,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Pan-TEAD (1:1000; #13295; CST),0.9,Accept,Experimental Usage
,CTGF,Unknown,Unknown,,,,,CTGF,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,"CTGF (1:500, ab6992, Abcam)",0.9,Accept,Experimental Usage
,Notch1,Rabbit,Unknown,,,,,Notch1,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution",0.9,Accept,Experimental Usage
,S518-Merlin,Rabbit,Unknown,,,,,S518-Merlin,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution,0.9,Accept,Experimental Usage
,"Na+,K+-ATPase",Rabbit,Unknown,,,,,"Na+,K+-ATPase",PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)",0.85,Accept,Experimental Usage
,NeuroD1,Unknown,Unknown,,,,,NeuroD1,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)",0.95,Accept,Experimental Usage
,Phospho-Rb Ser 780,,Polyclonal,,,,,Phospho-Rb Ser 780,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)",0.9,Accept,Experimental Usage
,pSmad3,Rabbit,Monoclonal,,,,,pSmad3,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-pSmad3, rabbit monoclonal Abcam Cat. # ab52903 RRID: AB_882596 1/200 dilution",0.9,Accept,Experimental Usage
,Zpr-1,Mouse,Monoclonal,,,,,Zpr-1,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody Zpr-1, mouse monoclonal Zebrafish International Resource Center Cat. # zpr-1 RRID: AB_10013803",0.9,Accept,Experimental Usage
,Zn-5,Mouse,Monoclonal,,,,,Zn-5,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody Zn-5, mouse monoclonal Zebrafish International Resource Center Cat. # zn-5 RRID: AB_10013770",0.9,Accept,Experimental Usage
,HuC/D,Rabbit,Polyclonal,,,,,HuC/D,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-HuC/D, rabbit polyclonal Abcam Cat. # ab210554 RRID: AB_210554 1/500 dilution",0.9,Accept,Experimental Usage
,PKC β1,Mouse,Monoclonal,,,,,PKC β1,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,"Antibody anti-PKC β1, mouse monoclonal Santa Cruz Biotechnology Cat. # SC-8049 RRID: AB_628143",0.9,Accept,Experimental Usage
,β-tubulin III,,,,,,FITC,β-tubulin III,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,β-tubulin III-FITC (neurofibroma presence),0.9,Accept,Experimental Usage
,Gal α 1-3Gal,Unknown,Unknown,,,Non-primate,Fluorescein,Gal α 1-3Gal,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS",0.85,Accept,Experimental Usage
,DARPP32,Unknown,Unknown,,,,,DARPP32,PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling) | Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",0.9,Accept,Experimental Usage
,p-MAPK,Unknown,Unknown,,,,,p-MAPK,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",0.9,Accept,Experimental Usage
,total MAPK,Unknown,Unknown,,,,,total MAPK,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)",0.9,Accept,Experimental Usage
,p-DARPP32,Unknown,Unknown,,,,,p-DARPP32,PMID:21963652 | PMID:24375753,10.1016/j.expneurol.2011.09.005 | 10.1002/ana.24093,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies | Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)",0.9,Accept,Experimental Usage
,Cy3/Cy5,,Monoclonal,,,,,Cy3/Cy5,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 h at room temperature",0.9,Accept,Experimental Usage
,DAXX,Rabbit,Polyclonal,,,,,DAXX,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,"Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies) was performed manually",0.95,Accept,Experimental Usage
,"HLA-A,B,C",,,,,Human,,"HLA-A,B,C",PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)",0.9,Accept,Experimental Usage
,H-2,,,,,Mouse,,H-2,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody",0.9,Accept,Experimental Usage
,human nuclei,,,,,Human,,human nuclei,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,"using the following antibodies: human nuclei (ab254080, Abcam)",0.9,Accept,Experimental Usage
,FAP,Unknown,Recombinant,,,Human,Non-conjugated,FAP,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250",0.9,Accept,Experimental Usage
,LAMA2,,,,,,,LAMA2,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)",0.95,Accept,Experimental Usage
,SLC22A3,,,,,,,SLC22A3,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)",0.95,Accept,Experimental Usage
,PRRX1,,,,,,,PRRX1,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)",0.95,Accept,Experimental Usage
,Phospho-p44/42 ERK1/2,Rabbit,Monoclonal,,,,,Phospho-p44/42 ERK1/2,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,0.95,Accept,Experimental Usage
,p44/42 ERK1/2,Rabbit,Monoclonal,,,,,p44/42 ERK1/2,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution,0.95,Accept,Experimental Usage
,phosphor-p44/p42 MAPK (ERK1/2),Rabbit,Monoclonal,,,,,phosphor-p44/p42 MAPK (ERK1/2),PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,"Immunohistochemical staining for phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Catalog #4370, Rabbit mAb, 1:100 dilution)",0.95,Accept,Experimental Usage
,p-ERK1/2,Rabbit,Monoclonal,,,,,p-ERK1/2,PMID:37681415 | PMID:24375753,10.1172/jci.insight.168445 | 10.1002/ana.24093,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. | Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,"p-ERK1/2 (CST 4370, clone D13.14.4E) | pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies",0.9,Accept,Experimental Usage
,EGFP,Mouse,Monoclonal,,,,,EGFP,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,"EGFP (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)",0.9,Accept,Experimental Usage
,c-Met,Rabbit,Polyclonal,,,,,c-Met,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz) | and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz",0.9,Accept,Experimental Usage
,phosphorylated c-Met,Rabbit,Polyclonal,,,,,phosphorylated c-Met,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen)",0.9,Accept,Experimental Usage
,mesothelin,,,,,,,mesothelin,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz),0.85,Accept,Experimental Usage
,phospho P-Met,,,,,,,phospho P-Met,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage
,MAPK,,,,,,,MAPK,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling",0.9,Accept,Experimental Usage
,p55/MPP1,Mouse,Monoclonal,,,Human,Non-conjugated,p55/MPP1,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected,0.9,Accept,Development
,NF-H,Rabbit,Polyclonal,,,Human,Non-conjugated,NF-H,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,rabbit anti-NF-H (Chemicon); and mouse anti-Caspr,0.8,Accept,Experimental Usage
,Caspr,Mouse,Unknown,,,Human,Non-conjugated,Caspr,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel",0.8,Accept,Experimental Usage
,CD11c,Unknown,Unknown,,,Human,Unknown,CD11c,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,CD19,Unknown,Unknown,,,Human,Unknown,CD19,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,CD163,Unknown,Unknown,,,Human,Unknown,CD163,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,CSF1R,Unknown,Unknown,,,Human,Unknown,CSF1R,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3...",0.9,Accept,Experimental Usage
,ColIA,,Monoclonal,,,,FITC,ColIA,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA) | All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI",0.85,Accept,Experimental Usage
,Abl,,,,,,,Abl,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)",0.9,Accept,Experimental Usage
,c-abl,,,,,,,c-abl,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"Total c-abl protein was detected using an antibody from BD Biosciences (Cat. no. 554148, San Jose, CA, USA)",0.9,Accept,Experimental Usage
,TGF-β,,,,,,,TGF-β,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer",0.9,Accept,Experimental Usage
,MAP2,Mouse,Unknown,,,,,MAP2,PMID:25535838 | PMID:36241865,10.7554/eLife.05151 | 10.1038/s12276-022-00850-9,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"MAP2 (1:1000, mouse, Sigma-Aldrich) | Anti-MAP2 antibody primary IF and WB CST",0.9,Accept,Experimental Usage
,NF-200,,,,,,,NF-200,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-NF-200 antibody primary IF and WB CST,0.85,Accept,Experimental Usage
,P-mTOR,,,,,,,P-mTOR,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-P-mTOR antibody primary WB CST,0.85,Accept,Experimental Usage
,Rictor,,,,,,,Rictor,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-Rictor antibody primary WB CST,0.85,Accept,Experimental Usage
,bcl2,Mouse,Monoclonal,,,Human,,bcl2,PMID:32948135 | PMID:36241865,10.1186/s12885-020-07397-w | 10.1038/s12276-022-00850-9,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO) | Anti-Bcl-2 antibody primary IF and WB CST",0.95,Accept,Experimental Usage
,myelin basic protein,,,,,,,myelin basic protein,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Anti-myelin basic protein (MBP) antibody primary IF and WB CST,0.85,Accept,Experimental Usage
,pErbB2,Unknown,Unknown,,,,,pErbB2,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,stained with pErbB2 (1∶50 dilution) as previously described [14],0.85,Accept,Experimental Usage
,Calbindin,Mouse,Unknown,,,,,Calbindin,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Calbindin (1:1000, mouse, Sigma-Aldrich)",0.9,Accept,Experimental Usage
,GABARα6,Rabbit,Unknown,,,,,GABARα6,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"GABARα6 (1:500, rabbit, Millipore)",0.9,Accept,Experimental Usage
,Tbr2,Rabbit,Unknown,,,,,Tbr2,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Tbr2 (1:1000, rabbit, Abcam)",0.9,Accept,Experimental Usage
,Calretinin,Mouse,Unknown,,,,,Calretinin,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"Calretinin (1:1000, mouse, Millipore)",0.9,Accept,Experimental Usage
,P27,Rabbit,Unknown,,,,,P27,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"P27 (1:250, rabbit, Santa Cruz Biotechnology, Dallas, TX)",0.9,Accept,Experimental Usage
,β-gal,Rabbit,Unknown,,,,,β-gal,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,"β-gal (1:1000, rabbit, 5 prime-3 prime, Gaithersburg, MD)",0.9,Accept,Experimental Usage
,BIM,Unknown,Polyclonal,,,Human,Non-conjugated,BIM,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"Antibodies: anti-human C-terminal BIM (goat, Bio-RAD, Hercules, CA, USA, AHP2074; 1:1000) | anti-human N-terminal BIM (C34C5) (rabbit, Cell Signaling, #2933; 1:1000)",0.9,Accept,Experimental Usage
,b-tubulin,Mouse,Monoclonal,,,,Non-conjugated,b-tubulin,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,"anti-b-tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1:10,000)",0.9,Accept,Experimental Usage
,COL4A,Unknown,Unknown,,,,,COL4A,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"KI-67 (prediluted; catalog 790-4286, Ventana), and COL4A (1:1000 dilution; catalog ab6586, Abcam)",0.9,Accept,Experimental Usage
,histone H3 (tri methyl K27),Unknown,Unknown,,,,,histone H3 (tri methyl K27),PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,"Immunolabeling for anti-histone H3 (tri methyl K27) (1:200 dilution; catalog ab6002, Abcam)",0.9,Accept,Experimental Usage
,XBP1,Unknown,Unknown,,,,,XBP1,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA)",0.9,Accept,Experimental Usage
,XBP1u,Unknown,Unknown,,,,,XBP1u,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)",0.9,Accept,Experimental Usage
,XBP1s,Unknown,Unknown,,,,,XBP1s,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,anti-XBP1s (Cell Signaling),0.9,Accept,Experimental Usage
,Parkin,Unknown,Unknown,,,,,Parkin,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)",0.9,Accept,Experimental Usage
,PINK1,Unknown,Unknown,,,,,PINK1,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)",0.9,Accept,Experimental Usage
,ATP5H,Unknown,Unknown,,,,,ATP5H,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)",0.9,Accept,Experimental Usage
,p21,Mouse,Monoclonal,,,Human,,p21,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)",0.95,Accept,Experimental Usage
,bcl6,Mouse,Monoclonal,,,Human,,bcl6,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)",0.95,Accept,Experimental Usage
,phospho-RB1 S807/811,Unknown,Unknown,,,,,phospho-RB1 S807/811,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"incubated with phospho-RB1 S807/811 antibody (Cell Signaling Technology, no. 8516, 1:1600)",0.9,Accept,Experimental Usage
,kappa light chain,Rabbit,Monoclonal,,,Mouse,,kappa light chain,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,"kappa light chain to identify plasma cells (rabbit monoclonal antibody, Sigma Aldrich, clone RM103, SAB5600201, 1:400)",0.9,Accept,Experimental Usage
,SIAH,Mouse,Monoclonal,,,,,SIAH,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody),0.85,Accept,Experimental Usage
,Ref-1,Mouse,Monoclonal,,,,,Ref-1,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"stained for Ref-1 (mouse Ref-1 antibody, 1:200 dilution, Novus Biologicals, 13B8E5C2)",0.95,Accept,Experimental Usage
,nitrated Hsp90,Unknown,Unknown,,,,,nitrated Hsp90,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56 (dilution 1:200),0.95,Accept,Experimental Usage
